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Abstract 
Bronchiolitis Obliterans (BO) is a major cause of chronic airway dysfunction after 
toxic chemical inhalation.  The pathophysiology of BO is not well understood, but 
epithelial cell injury has been closely associated with the development of fibrotic lesions 
in human studies and in animal models of both toxin- and transplant-induced BO.  
However, while almost all cases and models of BO include epithelial injury, not all 
instances of epithelial injury result in BO, suggesting that epithelial damage per se is not 
the critical event leading to the development of BO.  In this dissertation, we describe a 
model of chlorine (Cl2)-induced BO in which mice develop tracheal and large airway 
obliterative lesions within 10 days of exposure to high (350 ppm), but not low (200 ppm), 
concentrations of Cl2 gas. Lesions develop in a series of well-demarcated pathological 
changes that include epithelial denudation, inflammatory cell infiltration by day 2 after 
exposure, fibroblast infiltration and collagen deposition by day 5, and in-growth of 
blood vessels by day 7, ultimately leading to lethal airway obstruction by days 9-12.  
Using this model, we were able to test our hypothesis that loss of epithelial progenitor 
cells is a critical factor leading to the development of obliterative airway lesions after 
chemical inhalation. Indeed, these lesions arise only under conditions and in areas in 
which basal cells, the resident progenitor cells for large airway epithelium, are 
eliminated by Cl2 exposure.   
The molecular pathways contributing to BO development are not well 
understood. Mechanisms of epithelial injury differ across BO models, but we 
hypothesized that after the inciting injury, BO models share common pathways. We 
compared microarray analysis from day 5 non-BO- and BO-inducing chemical injuries 
and subsequently identified biological pathways that may contribute to BO 
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pathogenesis. Our findings add support to pathways previously implicated in BO 
development and more importantly, suggest potential new pathways and molecular 
mediators of BO.  Furthermore, we evaluated the efficacy of therapeutic inhibition of 
neovascularization or inflammation to prevent Cl2-induced BO. To date, our therapeutic 
interventions were ineffective. Nonetheless, our findings suggest that in the context of 
Cl2-induced BO, vascular endothelial growth factor receptor 2 (a mediator of 
neovascularization) and inducible nitric oxide synthase (a mediator of inflammation) are 
not critical in BO pathogenesis. 
In sum, our work introduces and characterizes a novel Cl2-induced murine 
model of BO. Using this model we demonstrated that in the absence of basal cells, 
epithelial regeneration does not occur and regions of epithelial denudation persist from 
which an aberrant repair process is initiated, leading to obliterative airway lesions. Our 
findings suggest that, irrespective of the cause, loss of epithelial progenitor cells may be 
a critical factor leading to the development of BO. Furthermore, our gene expression 
analysis implicates novel mediators and signaling pathways in the development of BO. 
Our analysis lays the foundation for more rigorous exploration of these targets in the 
pathogenesis of BO.   
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1. Overview  
A basic understanding of airway epithelium, bronchiolitis obliterans (BO), 
animal models of BO, and chlorine (Cl2) gas will be required to contextualize the 
research discussed herein. For this purpose, I have included an overview of each of these 
subjects.  
1.1 Airway epithelium homeostasis and repair 
Respiratory epithelium interfaces with the environment and serves as a critical 
physical and functional barrier to airborne particulate-matter, pollutants, and pathogens. 
To meet the challenges of constant environmental exposure, the epithelium has adopted 
a wide range of specialized effector cells, including secretory cells, ciliated cells and 
basal cells [1]. The diversity of the epithelium changes from proximal to distal airways, 
which likely reflects changing barrier and lung function requirements. Here, we will 
review airway anatomy and the cell types that comprise the respiratory epithelium.  
Additionally, the airways possess great capacity to repair after injury. We will discuss 
normal repair processes and the epithelial progenitors that contribute to the restitution 
of normal epithelium.  
The overall structure of the airways is much like the roots of a tree. Air travels 
down successively smaller airways from conducting to respiratory airways. The major 
conducing airways begin with the trachea before branching into bronchi, and then 
proximal bronchioles. The respiratory airways include distal bronchioles and branch 
into alveolar ducts and sacs where the majority of oxygen exchange occurs [2]. Cellular 
diversity changes along the length of the airway. In mice, proximal airways, including 
the trachea and bronchi, are comprised of pseudostratified epithelium [1]. Ciliated and 
secretory (Clara) cells line the airway and are located above a layer of basal cells.  
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Ciliated cells are columnar-shaped with cilia protruding into the lumen. These cells are 
critical for debris clearance, and they function in concert as a part of the mucociliary 
escalator that moves mucus and particulate matter up and out of the respiratory tract 
[3].  Ciliated cells decrease in numbers along the bronchioles. Clara cells are also 
columnar-shaped and secrete small molecules into the airway, including lung surfactant 
and Clara cell secretory protein [1]. These products serve to inactivate harmful 
substances that enter the airway. Basal cells are cuboidal-shaped cells that are situated at 
the bottom of the epithelium with wide bases that attach to the basal lamina. Strong 
evidence supports that basal cells are progenitor epithelial cells during homeostatic 
conditions and especially after injury [4]. The epithelium of the trachea and bronchi 
transitions from pseudostratified to simple columnar along the bronchioles and is 
mainly comprised of ciliated and Clara cells. Finally, the alveolar ducts and sacs are 
comprised of specialized epithelial Type 1 and Type 2 cells that are uniquely adapted to 
assist in gas exchange [1].  
Epithelium type and cell distribution vary among species. In contrast to the 
murine airways described above, human airways are lined by pseudostratified 
epithelium from the trachea down to the distal bronchioles, and these bronchioles are 
approximately 0.5mm in diameter when the epithelium transitions into simple cubodial 
epithelium that lack basal cells [5].  These disparities in anatomy are a challenge to 
researchers who are restricted to murine models for experimentation. In terms of size 
and cellular composition, the mouse trachea is representative of the first six generations 
of the human airways [5].  The mouse trachea, but not lower airways, contains basal 
cells that sit beneath the luminal epithelium and function similarly to human airway 
basal cells in their ability to give rise to epithelial cells during normal homeostasis and 
after injury [4, 6].  
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  Under normal homeostatic conditions, epithelial cell turnover is slow with less 
than 5% of cells proliferating concurrently [7]. However, the airway possesses great 
capacity for repair after injury. The repair response greatly depends on the severity of 
the injury, which can be broadly divided into four different degrees [8]. The first degree 
consists of cellular irritation, not resulting in death, and is thought to be reversible with 
minimal need for proliferation as a mechanism of repair.  The second degree inflicts 
partial necrosis or apoptosis of mature epithelial cells, and basal cells are unaffected. 
Repair primarily consists of a quick burst of proliferation from local mature epithelial 
cells or proliferation and differentiation of local progenitor cells. The third degree of 
injury involves the majority of mature epithelial cells undergoing necrosis or apoptosis 
and shedding from the airway wall; the majority of basal cells survive. This type of 
injury is evident after toxic gas inhalation, such as sulfur dioxide (SO2) and lower 
concentrations of Cl2 [9, 10]. The fourth degree of injury is similar to the third, except 
that the majority of basal cells do not survive.  This type of injury is most often seen in 
large areas of mechanical injury or even after inhalational exposure to high 
concentrations of chemicals [10, 11]. It is important to note that the injury inflicted by 
inhalational irritants is often dependent on toxicant dose and duration of exposure.  
In response to injuries involving desquamation, normal epithelial repair is 
thought to occur in three stages [12-14]. First, basal cells spread and migrate to cover 
denuded epithelium.  Second, these cells proliferate, with self-renewing basal cells 
remaining near the basal lamina and daughter cells forming upper layers of transitory 
squamous metaplasia.  Lastly, the upper layers remodel to form a pseudostratified layer 
of mature, differentiated mucociliary epithelium. It is important to note that the exact 
epithelial progenitor cells responsible for repair vary along the airway and into the lung; 
identification of these progenitors is an active area of research [14, 15].  However, 
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extensive epithelial lineage tracing implicates basal cells as the primary progenitor in the 
pseudostratified epithelium of mice after desquamation of the airways [4, 5].  
1.2 Bronchiolitis obliterans 
BO is a form of chronic obstructive airway disease in which small airways are 
compressed and narrowed by fibrosis and inflammation. The resulting fixed airway 
obstruction leads to dyspnea, typically on exertion, which is often progressive [16-18]. 
Currently, BO is the most prominent feature of chronic rejection after lung 
transplantation and is the leading cause of death beyond the first year post transplant 
[18, 19].  Lung transplantation is the most recognized cause of BO, but less recognized 
causes include collagen vascular disease, gastroseophageal reflux, inhalation of toxic 
chemicals, viral infections, and hematopoetic stem cell transplantation [16, 20]. In the 
case of toxin inhalation, BO has been documented following exposures to a wide variety 
of chemicals, including Cl2, ammonia, methyl isocyanate, mustard gas, and diacetyl, the 
cause of "popcorn worker's lung" [21, 22].   
Diagnosis of BO is often difficult, relying on a combination of clinical and 
physiological parameters. The hallmark clinical finding is reduced forced expiratory 
volume in 1 second (FEV1) in the absence of other identifiable causes [20].  It is common 
for BO to develop in patches, making it possible to go undiagnosed in transbronchial 
biopsies. Additionally, no diagnostic guidelines exist for BO identification via 
radiographic findings, although expiratory CT scans may aid in identifying air-trapping 
that can occur from small airway narrowing [20]. Because diagnosing BO is often 
difficult, its true incidence may be underestimated.  In one recent study, 78% of U.S. Iraq 
and Afghanistan veterans who presented with unexplained dyspnea and underwent 
lung biopsy had pathologic evidence of BO, despite, in most cases, having normal chest 
x-rays and pulmonary function tests [23]. 
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Pathologically, BO can be divided into two forms: proliferative and constrictive. 
In proliferative BO, connective tissue breeches the airway lining and then proliferates 
within the lumen to form tissue masses, akin to granulation tissue [24].  This is often 
seen as an acute inflammation-mediated process and, in some cases, responds to 
corticosteroid treatment [16].  In contrast, constrictive BO is an irreversible fibrotic 
thickening of the submucosa that concentrically constricts the small airways from 
beneath the airway epithelial lining [16]. It is not clear whether constrictive BO is the 
final outcome of persistent and severe proliferative BO, or if these represent distinct 
responses to differing types of airway injury [25]. To date, therapeutics for constrictive 
BO have met with limited success and serve mostly to slow the progression of the 
disease, not cure it.  The majority of therapeutics are immunosuppressants, including 
cyclosporine, azithromycin (an antibiotic that also suppresses activation of myeloid 
cells), statins, and aggressive prevention of known risk factors such as gastroesophageal 
reflux and infections [20, 26, 27]. Even so, constrictive BO is associated with high 
mortality [17, 18].   
BO is a complex disease that can arise from multiple factors, including ischemia, 
inflammation, immune-mediated rejection and epithelial injury. The interplay between 
these factors in the pathogenesis of BO remains unclear. Tissue ischemia can be induced 
by transplantation and anti-endothelial immune responses. Recent studies demonstrated 
that reducing lung transplant ischemia by revascularizing bronchial arteries, in addition 
to the pulmonary artery, resulted in fewer incidents of acute rejection and infection, and 
delayed the onset of BO[28, 29]. This study directly implicates transplant ischemia as an 
inciting factor of BO. It is proposed that ischemia-induced hypoxia leads to 
inflammation, another BO-associated factor. Immune cells are capable of oxygen sensing 
through intracellular accumulation of hypoxia inducible factors (HIFs); HIFs enhance 
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cell activation and inflammatory functions [30]. It has been proposed that hypoxia 
perpetuates a pro-inflammatory environment that is permissive to innate immune cell-
mediated tissue damage and/or the development of alloimmune rejection of donor 
tissue. In the case of immune-mediated rejection, acute rejection is a well-documented 
risk factor for BO after lung transplant. A recent study demonstrated that as few as one 
incidence of minimal acute rejection significantly increased the risk of BO 
complications[31].  Rejections can initiate compliment cascades and inflammation that 
lead to tissue damage [32-34].  Additionally, pulmonary infection is a significant risk 
factor for BO after transplant [20, 35]. It is thought that the immune response to the 
pathogen induces pro-inflammatory cytokines and increases antigen presentation at the 
site of infection, creating an environment conducive to alloreactive T cell priming and, 
ultimately, graft rejection [35].  
The common theme to all these inciting factors is tissue damage, from which 
aberrant fibrotic responses progress into BO.  More specifically, several lines of evidence 
suggest that epithelial cell injury is the most critical pathogenic factor.  In a mouse model 
of allogeneic mismatched orthotopic lung transplantation characterized by severe 
vascular rejection but no epithelial injury, obliterative airway disease did not occur [36]. 
However, in a mouse tracheal transplant model, an alloresponse to epithelium was 
sufficient to induce obliterative airway disease [37]. In non-transplant murine studies, 
chronic depletion of mature epithelial cells, either Clara cells or Type II alveolar cells, 
results in abnormal re-epithelialization and a fibrotic response [38, 39]. In the case of 
chemical-associated BO, epithelial injury is also a common feature of almost all human 
instances and animal models, further supporting the view that epithelial damage is a 
critical factor in the pathogenesis of BO.  The research herein investigates mechanisms 
through which chemical-induced epithelium injury initiates BO. 
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1.3 Animal models of bronchiolitis obliterans 
Several animal models of BO have emerged over the past two decades, each with 
their own advantages and limitations. It is generally agreed that large animal models 
such as pigs are apt to be the most clinically relevant due to their anatomic similarity to 
humans, but such models are labor intensive, low throughput and extremely costly. To 
overcome those challenges, small rodent models were created; however, the size 
discrepancy between human and rodents has been a persistent criticism. Here, we will 
briefly discuss the various small animal models of transplant and non-transplant BO. 
Transplant animal models of BO include both heterotopic and orthotopic 
transplantation of tracheas, lungs, and bone marrow [40]. The most common model is 
heterotopic transplantation, which involves excising the trachea and implanting it 
intraperitoneally or subcutaneously in an allogenic or syngenic recipient mouse. The 
development of BO is alloimmune-dependent as syngenic transplants are protected [19, 
41]. Approximately 10 days post transplant, the allograft exhibits epithelial damage and 
immune cell infiltration. At 21 days, tissue remodeling is evident with granulation-like 
tissue obstructing the lumen. The major advantages of the model are its reproducibility, 
technical simplicity, and gross similarity to the human disease pathology. However, 
there are major disadvantages. Unlike in humans, the allograft is subjected to immediate 
tissue ischemia (depending on diffusion from the surrounding extrapulmonary 
environment), is no longer a functioning conduit for ambient air, and is removed from 
the influence of the pulmonary-specific milieu. 
 Orthotopic tracheal transplantation overcame the disadvantages of heterotopic 
transplantation in that a section of a donor trachea surgically replaces the trachea of an 
allogenic recipient. This allows the allograft to remain an integral part of the airway. 
Disadvantages of this model are that it is technically very difficult, and BO development 
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is less reproducible [19]. In contrast to the heterotopic model, the majority of othotopic 
transplants does not develop BO, or develops a less severe BO [36].  Further 
investigation revealed that the allografts were reepithelialized with recipient-derived 
epithelium, preventing immune-mediated epithelial cell death. Restoration of the 
epithelial barrier was enough to prevent BO. This model demonstrates the critical 
importance of epithelial integrity in the pathogenesis of BO. 
BO lesions have also been reported in an orthotopic bone marrow 
transplantation model. This model involves lethally irradiating mice, then transferring 
back bone marrow cells back with or without spleenic T cells. Two months post 
transplant, 15-50% of mice showed evidence of BO. This model is also dependent on 
alloimmune mechanisms. However, such low frequencies of BO development would 
require large cohorts of mice to ensure statistical significance of findings, decreasing its 
feasibility for testing therapeutics. 
 Non-transplant models of BO include the administration of toxins, many of 
which arose from clinical findings in humans who were accidently exposed to various 
irritants that resulted in BO. For instance, the chemical papaverine was implicated in the 
development of BO in a cohort of humans after they consumed raw plants that 
contained high levels of the compound [42].  Intratracheal installation of papaverine in 
rats led to BO development by 4 weeks post exposure [43]. Human clinical observations 
have led to similar BO models using chronic aspiration of gastric fluid in rats, oral 
administration of oleic acid in dogs, intratracheal installation of diacetyl in rats, and 
toxic gas inhalation in mice [10, 22, 44, 45]. Commonly reported events preceding BO 
development include epithelial damage, sometimes to the extent of denudation, and 
increased inflammatory cell infiltration into the airways. The major advantages of non-
transplant models of BO are their technical simplicity, the airways remain functional and 
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exposed to the pulmonary milieu, and BO pathogenesis, especially fibrotic responses, 
can be studied in the absence of robust alloimmune responses. However, most of the 
studies characterizing these models were highly descriptive, with a major focus on late-
stage BO identification. The studies lacked comprehensive analysis of early events that 
contribute to BO pathogenesis.  
1.4 Chlorine: an industrial commodity and a pulmonary toxicant  
Inhalation of toxic chemicals, such as Cl2, can result in mild to severe lung 
dysfunction or even death[46]. Cl2 is one of the top manufactured toxic gases in the 
world and is primarily used in the production of industrial products. The U.S. produces 
around 15 million tons of Cl2 each year [47]. Typically, Cl2 is transported and stored in 
large quantities, making spills and ruptures of Cl2 containers a potential risk to nearby 
residential areas[47]. In one instance, a train derailed in Graniteville South Carolina, 
releasing 42-60 tons of Cl2 gas. Nine exposure victims died, and 71 victims were 
hospitalized[48]. The most common exposures occur as occupational hazards or when 
mixing common household cleaners[49, 50]. Besides accidental exposures, Cl2 gas was 
and is currently utilized in warfare and terrorism[47, 51]. As a result of its easy 
accessibility and toxicity, the U.S. government listed Cl2 gas as a likely chemical agent 
for use in chemical attacks, making development of therapeutics for Cl2 gas inhalation of 
great importance[52].  
Direct mechanisms by which Cl2 causes lung injury are better understood than 
indirect mechanisms. Cl2 is a water-soluble greenish-yellow gas that preferentially 
dissolves into the upper airways where it depletes anti-oxidants then generates reactive 
intermediates (HOCl and OCl-) and chloromines. These toxic agents damage and disable 
proteins, inhibit Na+-dependent fluid clearance, and increase epithelium permeability 
and death[53, 54]. Anti-oxidant treatments were shown to successfully curtail the 
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chlorination of biological molecules by inhibiting the generation of Cl2 intermediates and 
thus mitigating direct mechanisms of Cl2 injury[55]. Indirect mechanisms are not clearly 
understood, but studies have highlighted the importance of inducible nitric oxide 
synthase (NOS2, an enzyme known to catalyze copious amounts of nitric oxide). The 
role of NOS2 in Cl2 injury will be discussed in greater detail in Chapter 4. 
In humans, predominant physiological responses to Cl2 gas inhalation are 
wheezing, dyspnea, increased airway hyperreactivity (AHR) and hypoxia that, short-
term, are consistent with acute lung injury and, long-term, can develop into reactive 
airways dysfunction syndrome (RADS) [47, 48]. Immediate medical treatment for Cl2 
exposure focuses on decontamination and alleviating symptoms instead of directly 
combating pathologic causes. Supportive care includes oxygen support and 
bronchodilators to control airway constriction[56]. The majority of exposure victims 
have transient lung abnormalities that return to normal within a few days or weeks after 
exposure,[50, 56] but there are studies that report persistent declines in lung function in 
a portion of exposure victims. A study by Schwartz et al. followed 13 construction 
workers who were accidentally exposed to Cl2 gas. Twelve years after exposure, 5 of the 
13 workers exhibited persistent elevated AHR[57]. Another study by Bherer et al. 
evaluated 71 workers who had been repeatedly exposed to Cl2 over the span of several 
months. Eighteen to 24 months post exposure, 41% of the workers exhibited elevated 
AHR[58].  
In sum, as a leading industrial commodity, Cl2 contributes greatly to the health 
and convenience of modern society. It is used in the production of plastics, paper, and 
other goods, and its strong disinfecting properties are employed as a major method of 
water purification. Such ubiquitous handling of Cl2 mutually increases the potential of 
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occupational and domestic exposures.  Further research is required to identify and 
develop therapeutics that target specific mechanisms of Cl2-induced airway injury.  
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2. Loss of basal cells precedes bronchiolitis obliterans­like 
pathological changes in a murine model of chlorine gas 
inhalation 
2.1 Introduction 
The exact pathogenesis of BO remains unclear. As mentioned above, potential 
contributing factors include innate and adaptive immune responses, tissue ischemia, 
and chronic epithelial cell injury [37, 59-61]. Specifically, epithelial injury is a common 
feature of almost all human instances and animal models of toxic chemical inhalation 
associated with the development of BO, supporting the view that epithelial damage is a 
critical factor in the pathogenesis of BO.  However, evidence suggests that epithelial 
injury per se is not sufficient for the development of BO.  Some animal models 
demonstrate widespread death of epithelial cells, but repair normally with no evidence 
of fibrotic lesion development.  In animal models that display obliterative airway 
lesions, both the frequency and the anatomic distribution of these lesions is much less 
than the extent of epithelial damage.  These findings suggest that some factor beyond 
acute epithelial cell injury is required for the development of BO. We previously 
mentioned 4 degrees of epithelial injury, the last of which kills epithelial progenitor cells 
called basal cells. We hypothesized that basal cell death is the critical factor that initiates 
BO pathogenesis. 
Here, we describe a novel murine model in which obliterative airway lesions 
with the pathologic appearance of proliferative BO rapidly develop in the tracheas and 
primary bronchi of mice exposed to high doses of Cl2 gas.  The sequence of cellular 
events that occurs during the development of these obliterative airway lesions includes 
epithelial cell death, failure of re-epithelialization, inflammatory cell infiltration, 
fibroblast infiltration, collagen deposition, and angiogenesis, ultimately leading to lethal 
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airway obstruction within 10 days.  Moreover, in a comparison of different doses of Cl2 
exposure, we determined that the BO lesions only develop under conditions and in areas 
in which basal cells are eliminated by toxic gas exposure.  In the absence of basal cells, 
epithelial regeneration does not occur and regions of epithelial denudation persist, from 
which an aberrant repair process is initiated that leads to obliterative airway lesions.  
Our findings suggest that, irrespective of the cause, loss of epithelial progenitor cells 
may be a critical factor leading to the development of BO. Results in this chapter have 
been reprinted with permission of the American Thoracic Society[10].   
2.2 Materials and methods  
Mice and survival studies. Mice were 8-9 week-old C57Bl/6 females, purchased 
from Charles River Laboratories (Wilmington, MA). CX3CR1GFP/GFP mice were provided 
by D. Littman (New York University, New York, NY) and crossed with C57Bl/6 mice to 
produce CX3CR1+/GFP mice. All animal experiments were conducted in accordance with 
National Institutes of Health guidelines and protocols approved by the Animal Care and 
Use Committee at Duke University.  
Chlorine exposure. 1% percent Cl2 in nitrogen was purchased from Airgas 
National Welders (Research Triangle Park, NC). Mice were placed within individual 
holders and exposed for a 30 minute duration to Cl2 (Airgas National Welders, 1% Cl2 in 
nitrogen) or filtered air (FA) via a nose-only inhalation chamber (Figure 1).  Cl2 
concentrations within the chamber were regulated upstream by mixing 1% Cl2 gas into 
filtered air and were calibrated to deliver Cl2 concentrations specifically between 175 to 
350 ppm.  Control mice were exposed to FA under the same experimental conditions 
of temperature and relative humidity.  After exposure, mice were returned to vivarium 
housing and monitored during recovery periods ranging between 1-14 days. 
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Histology and immunofluorescence. For trachea dissection, the airways were 
exposed via a midline incision through the skin and peritoneum extending through the 
rib cage and up to the epiglottis. The trachea was exposed, and the rib cage was opened 
along the midline of the sternum. The heart was removed; then the airway-esophagus 
combination was removed and cut free below the epiglottis. The tissue was washed 
briefly in PBS to remove blood. The esophagus and lung tissue were separated from the 
trachea. To remove air bubbles, PBS was gently pushed though the remaining airway 
with a 23 gauge needle and 3 ml syringe. Tracheas were fixed in 4% paraformaldyhde 
for 3 hours at 4 degrees C. For paraffin sections, tissues underwent PBS washing, alcohol 
dehydration, xylene clearing and paraffin embedding. Sections were cut 8µm thick and 
then stained with hematoxylin and eosin (H&E). For frozen sections, tissues were 
washed with PBS several times then washed in 15% and 30% sucrose, respectively, for 1 
hour. Tissues were left overnight in half 30% sucrose, half OCT at 4 degrees C then 
embedded into OCT. Tracheas were serially cut into 12µm thick cross sections, 
proximally to distally. Frozen tissues were stained with H&E or the primary anti-bodies: 
rabbit anti-cytokeratin 5 (Covance, Emeryville, CA), rat anti-e-cadherin 
(Zymed/Invitrogen, Grand Island, NY), rat anti-CD31 (BD Pharmingen, San Jose, CA), 
rat biotinylated anti-CD11b (Biolegend, San Diego, CA), rabbit biotinylated anti-collagen 
I (Rockland, Gilbertsville, PA). Fluorescence-conjugated secondary antibodies were all 
from Molecular Probe/Invitrogen (Grand Island, NY). Images were taken with an 
inverted confocal laser scanning microscope (Zeiss LSM 510; Carl Zeiss, Jena, Germany). 
To maintain high resolution of complete tracheal rings, multiple images of tracheal 
sections were taken at low magnification and then layered to create a composite image. 
In some composites, peritracheal tissues were omitted. 
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Quantification of epithelium. The length and thickness of tracheal epithelium 
was measured in photomicrographs of distal tracheal sections using the ruler function 
on the Zeiss LSM image browser. All analyzed tracheal sections were cut from the distal 
trachea. For the quantification of % epithelialized circumference on day 5 post Cl2, the 
total distance of tracheal circumference that stained positive for e-cadherin or 
cytokeratin 5 was divided by the total tracheal circumference as measured along the 
basal lamina. Epithelial thickness was measured at 200µm intervals around the total 
length of e-cadherin+ or cytokeratin 5+ epithelium in each transverse tracheal section.  
Areas of denuded epithelium were not included in thickness quantification.  
Sulfosuccinimidobiotin tracheal labeling. Mice were restrained and nose-only 
exposed to either 200 or 350 ppm Cl2 for 30 minutes. On day 4 after exposure, mice were 
anesthetized by ketamine (100 mg/kg)/xylazine (10 mg/kg) i.p. and then given 0.25mg 
of EZ-Link Sulfo-NHS-Biotin, No-Weigh Format (Sulfo-NHS-Biotin) (Pierce 
Biotechnology, Rockford, IL, USA) intranasally in a total of 30ul. Immediately before 
administration, Sulfo-NHS-Biotin was reconstituted with molecular grade water. 
Tracheas were harvested either 4 hours or 3 days after Sulfo-NHS-Biotin administration 
(corresponding to day 4 or day 7 post Cl2 exposure, respectively). Tracheas were 
processed as frozen sections then stained, and imaged as described above.  
For quantification of subepithelial Sulfo-NHS-Biotin staining, one cross section 
per trachea (from the distal region) was analyzed using the Zeiss LSM image browser.  
The length of biotin staining was defined as the length of the basal lamina under which 
consecutive biotin staining was present.  Non-consecutive biotin stains in the same 
tracheal cross section were counted as independent stains.  The length of lesions was 
defined as the length of the basal lamina along which intraluminal lesion was present. 
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Tracheal cell isolation and flow cytometric analysis. Tracheas were dissected 
(same as stated above), cleaned of surrounding connective tissue, cut into several 
smaller pieces and then digested for 40 minutes in media containing: 1.5 mg/ml 
collagenase, .4 mg/ml DNase I, 5% FBS and 10mM HEPES in HBSS. Tissues were gently 
vortexed every 10 minutes during incubation. The disassociated tissue was strained 
through a 70µm cell strainer. Cells were washed with PBS then counted, 1.0-5.0 x 106 
cells were stained in PBS with Live/Dead Aqua (Molecular Probes). Cells were washed 
then blocked for 10 minutes at 4 degrees C in a blocking buffer: 10 mM EDTA, 1% BSA, 
5% normal mouse serum, 5% normal rat serum, and 1% Fc block (eBioscience, San 
Diego, CA) in PBS. Cells were stained with antibodies for 30 minutes, total volume 
100ul, then washed three times and analyzed using a BD LSRII flow cytometer (BD 
Pharmingen, San Jose, CA). Antibodies used included: CD45-Qdot605, CD31-eflour450, 
and Ly6G-AF700 from eBioscience and CD11b-PE-Cy7, Ly6C-V450 from BD 
Pharmingen (BD Pharmingen, San Jose, CA)). Although cells were stained with CD31 
and Ly6C, neither of these markers were used for specific gating. Neutrophils were 
gated on singlets, CD11b+, Ly6G+ cells. Non-neutrophil myeloid cells were gated on 
singlets, CD11b+, Ly6G- cells. 
Statistics. Numerical data are presented as mean, mean ± SD, or mean ± SEM, as 
indicated in the figure legends. The comparison between survival curves was performed 
with the log-rank test using GraphPad Prism software (GraphPad, San Diego, CA). All 
data are analyzed by Student’s t tests using Prism software, as indicated in the figure 
legends. Pearson correlation coefficients were generated using Prism software. 
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2.3 Results 
2.3.1 Obliterative airway lesions develop in mice exposed to high 
dose Cl2 
We developed a model of Cl2-induced lung injury in which up to six mice can be 
simultaneously exposed to a given concentration of Cl2 gas by nose-only inhalation 
(Figure 1).  In preliminary dose-ranging studies, we determined that exposure to 175-250 
ppm Cl2 for 30 minutes results in minimal acute mortality.  However, during our 
studies, we observed that a small number of mice exposed to Cl2 appeared to 
symptomatically recover from the acute effects of Cl2, but then developed severe 
respiratory distress requiring euthanasia on days 6-12.  A similar unexplained late 
mortality in Cl2-exposed mice has been described previously [62]. To further explore this 
phenomenon, mice were exposed to a higher dose of Cl2 (350ppm for 30 min).  Rather 
than recover, 75% of mice exposed to 350ppm Cl2 develop a distinct pattern of labored 
breathing between days 6-12 which progresses to severe respiratory distress requiring 
euthanasia within 24 hours (Figure 2A).  In comparison, only 16% of mice exposed to 
200ppm Cl2 require euthanasia (Figure 2A).  On pathological examination, all of the mice 
that develop labored breathing display grossly visible obliterative airway lesions.  These 
lesions occur most commonly in the lower third of the trachea and in the main stem 
bronchi and have the appearance of granulation tissue.  In transverse histological 
sections of the tracheas, obliterative airway lesions occlude greater than 80% of the 
airway lumen (Figure 2B).  These obliterative lesions contain both connective tissue and 
inflammatory cells and display incomplete epithelial coverage at the lesion/airway 
interface (Figure 2C).  Overall, the cellular composition and appearance of these lesions 
closely resemble the histopathology of human proliferative BO lesions [63].   
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Figure 1: Nose-only restraints and exposure apparatus. 
Mice were individually restrained in tubes that were specially designed such that the 
nose of the mouse protrudes from the tube.  The nose-only mouse restraints fit securely 
into one of six available holders that access the interior of the exposure chamber.  When 
properly loaded, only the mouse’s nose protrudes into the exposure chamber.  Gas flow 
into the chamber is regulated by Cole Palmer flow meters.  Filtered air runs through the 
first flow meter at 4 L/min. 1% Cl2 balanced in nitrogen runs through the second flow 
meter at varied rates.  The output from the regulators are mixed just prior to entering the 
top of the exposure chamber.  The bottom of the exposure chamber is vented into the 
fume hood exhaust. 
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Figure 2: High concentrations of Cl2 induce lethal obliterative airway lesions. 
A) Survival after exposure to filtered air (n=3 mice), low dose Cl2 (200ppm, n=6), or high 
dose Cl2 (350ppm, n=24).  p=.0337 between high and low dose survival curves by log-
rank test.  B) Transverse sections from an unexposed trachea and a mouse euthanized 9 
days after high dose Cl2.  Sections 1-5 indicate order of sections, anterior to posterior. 
Sections are representative of 16 tracheas similarly examined. Scale bar is 200µm. C) Day 
9 blockage exhibiting abnormal re-epithelialization (arrows), connective tissue (C.T.) 
invasion and nearly complete occlusion of the lumen (asterisk).  Scale bar is 200µm. 
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2.3.2 Lesion formation coincides with basal cell but not luminal 
epithelial cell death  
To determine if the increased frequency of obliterative airway lesions in mice 
exposed to 350ppm Cl2 is due to more severe epithelial injury in these animals, we 
compared the fate of airway epithelium in mice exposed to low (200 ppm) and high (350 
ppm) Cl2.  Three hours after low dose Cl2 exposure, tracheas display large regions in 
which luminal epithelial cells (ciliated and Clara cells) are necrotic and are beginning to 
slough off (Figure 3B,H).  By 24 hours, the necrotic epithelium sloughs off, revealing a 
thin layer of simple squamous cells (Figure 3C,I).  In contrast, 3 hours post high dose Cl2 
exposure, many regions contain luminal epithelial cells that are swollen and lack cilia 
but remain attached to the tracheal wall (Figure 3H,K).  By 24 hours, the epithelium is 
still attached but is clearly necrotic; it displays widespread cellular swelling and loss of 
nuclei (Figure 3E,L).  Over the next 10 days, the great majority of mice exposed to low 
dose Cl2 display complete epithelial repair with no evidence of fibrotic lesions (data not 
shown), while mice exposed to high dose Cl2 develop obliterative airway lesions.   
These findings suggest that acute epithelial damage alone is not sufficient to 
induce obliterative airway lesions.  This view is consistent with our findings in a 
different model of toxic chemical exposure, SO2 inhalation, which we have previously 
described in detail [1, 4].  As with 200 ppm Cl2, mice exposed to SO2 display widespread 
luminal epithelial necrosis, sloughing of epithelium revealing a layer of simple 
squamous cells, and complete epithelial repair after 14 days, with no evidence of 
obliterative lesion formation [4].  In this model, we observed that tracheal basal cells 
survive SO2 exposure, proliferate, and give rise to relatively large patches of descendants 
that include both Clara and ciliated cells, thus acting as the progenitor cells for tracheal 
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epithelium after chemical injury.  Recent evidence suggests that basal cells also act as the 
progenitor cells for epithelial repair after Cl2 inhalation [64].  
To determine if the differences in epithelial repair we observe in mice exposed to 
low versus high doses of Cl2 are due to differences in basal cell survival, we examined 
tracheas for the presence of basal cells after low and high dose Cl2 exposure.  
Immunohistochemical staining with anti-e-cadherin marks both luminal epithelial and 
basal cells.  To specifically identify basal cells we co-stained with anti-cytokeratin 5, a 
basal cell-specific marker.  Our analysis demonstrates that basal cells remain viable and 
present in normal numbers, relative to unexposed mice, after low dose Cl2 exposure 
(Figure 3G,J).  In these sections, most of the mature columnar, luminal epithelium (e-
cadherin+ cytokeratin 5-) is absent and the epithelium replacing it consists primarily of 
basal cells (e-cadherin+, cytokeratin 5+).  In contrast, mice exposed to high dose Cl2 
display numerous large areas of trachea that are completely devoid of cytokeratin 5+ 
basal cells (Figure 3M).  The epithelial cells in these regions remain attached, are 
swollen, and display faint e-cadherin+ staining, but no longer have nuclei at 24 hours 
post injury (Figure 3L).  These findings strongly suggest that the chemical-induced loss 
of basal cells is a critical event in the course of toxin exposure.  It is known that if basal 
cells remain viable, they can serve as a source of progenitor cells for rapid epithelial 
repair.  Here, we propose that in the absence of basal cells, re-epithelialization does not 
occur and a fibrotic response is initiated. 
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Figure 3: Exposure to high Cl2 results in basal cell death. 
Photomicrographs of H&E-stained tracheas from unexposed mouse (A,F); after low dose 
Cl2; 3 hrs (B,H), 24 hrs (C,I); or after high dose Cl2; 3 hrs (D,K), 24 hrs (E,L).  
Immunofluorescent staining of: uninjured trachea (G), 24 hrs after low (J) and high (M) 
dose Cl2. E-cadherin (green), cytokeratin 5 (red), DAPI (blue).  Panels are representative 
of 5-6 tracheas at each time.  Scale bar is 20µm for A-E and 25µm for F-M.  Asterisks 
denote a fixation artifact. 
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2.3.3 Basal cell loss correlates with reduced tracheal re-
epithelialization 
To determine the consequences of basal cell loss on epithelial repair, 
inflammation, and fibrosis, we examined the time course of these events in mice exposed 
to low and high dose Cl2.  In general, normal epithelial repair is thought to occur in three 
stages [12, 13, 65].  First, basal cells spread and migrate to cover denuded epithelium.  
Second, these cells proliferate, with self-renewing basal cells remaining near the basal 
lamina and daughter cells forming upper layers of transitory squamous metaplasia.  
Lastly, the upper layers remodel to form a pseudostratified layer of mature, 
differentiated mucociliary epithelium. 
By day 5 after Cl2 exposure, it is clear that low and high dose Cl2-exposed 
tracheas undergo markedly different rates of epithelial repair.  After low dose Cl2 
exposure, the entire trachea is reepithelialized; the thickened e-cadherin+ luminal 
epithelium with basal cells (e-cadherin+ cytokeratin 5+) residing near the basal lamina is 
characteristic of the second phase of epithelial repair (Figure 4A).  There is no evidence 
of cellular migration into the lumen.  In contrast, by day 5 after high dose Cl2 exposure, 
necrotic epithelium is no longer attached to the airway wall, but, on average, 49% of the 
tracheal circumference lacks both mature epithelium and basal cells, as indicated by the 
absence of e-cadherin and cytokeratin 5 staining (Figure 4B, insets 4 and 6, 4F).  In those 
areas that do contain epithelium, this consists of a single layer of cells, some of which are 
cytokeratin 5+, indicating the presence of basal cells (Figure 4B, insets 3 and 5).  On 
average, the epithelium is 50% less thick than after low dose Cl2 exposure (Figure 4E).  
These observations suggest that even in areas where basal cells survive, their decreased 
numbers significantly retard epithelial repair.  In large areas of epithelial necrosis caused 
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by high dose Cl2, the basal lamina is exposed to the lumen, whereas after low dose Cl2 
exposure, it is covered by regenerating epithelium (Figure 4C,D).  In addition, by day 3 
after high dose Cl2 exposure, the necrotic epithelium that initially remained adherent to 
the tracheal wall becomes displaced into the lumen where it is retained as a mass of 
necrotic cells (Figure 4D). 
By day 7 after low Cl2 exposure, the trachea remains fully epithelialized.  Most of 
the transitory squamous metaplasia has remodeled into normal pseudostratified 
epithelium (Figure 4G,I).  In contrast, after high Cl2, the epithelium forms disorganized 
patches, varying in stages of repair (Figure 4H,J).  In some areas, connective tissue has 
fused with the trachea wall, preventing re-epithelialization of the original basal lamina.  
Additionally, the epithelium has begun surrounding the invading connective tissue in 
places, but there are still denuded areas where obliterative lesions interface directly with 
airspace.  
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Figure 4: Basal cell loss results in aberrant re-epithelialization. 
Immunofluorescent staining of epithelium 5 days after low (A) or high (B) dose Cl2. Two 
individual tracheas are shown in B. Boxed areas in top row are magnified in the bottom 
row and correspond by number. E-cadherin (green), cytokeratin 5 (red), DAPI (blue).  
Scale bar is 200µm. H&E staining of epithelium 5 days after low (C) or high (D) dose Cl2. 
Epithelium is denoted by black arrows and denuded epithelium by arrowheads. Scale 
bar is 50µm. Quantification of % epithelialized tracheal circumference (E) and epithelial 
thickness (F) 5 days after exposure to low or high dose Cl2 (n=3; *, p<0.05 by student’s t 
test, data are presented as mean ± SEM).  Immunofluorescent staining of epithelium 7 
days after low (G,I) or high (H,J) dose Cl2. Scale bar is 200µm for G and H. Scale bar is 
25µm for I and J. All panels are representative of 5-6 tracheas at each time. 
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2.3.4 Obliterative lesions originate from areas of denuded epithelium  
While the above findings demonstrate an overall association between the 
occurrence of epithelial denudation and the formation of obliterative airway lesions, 
they do not directly demonstrate that obliterative lesions arise from areas of epithelial 
denudation.  To address this issue, we developed a technique that would allow us to 
track the fate of individual lesions in individual animals.  To label areas of epithelial 
denudation, we administered sulfosuccinimidobiotin (Sulfo-NHS-biotin) to mice 
intranasally 4 days after low or high dose Cl2 exposure.  Sulfo-NHS-biotin is comprised 
of esters of biotin that are highly reactive, cell impermeable, and form stable amide 
bonds with primary amines found on the surfaces of living and non-living organic 
material [66].  To confirm that this technique specifically labels areas of epithelial 
denudation, tracheas were harvested 4 hours after Sulfo-NHS-biotin administration (on 
post exposure day 4) and stained with anti-e-cadherin and streptavidin to localize intact 
epithelium and covalent biotin attachment, respectively.   
All tracheas harvested 4 hours after Sulfo-NHS-biotin administration 
demonstrate uniform staining for biotin on epithelial surfaces.  In addition, there is 
biotin staining of exposed basement membrane areas and/or subepithelial connective 
tissue that is highly dependent on the presence and extent of epithelial denudation.  
Tracheas with no visible epithelial denudation typically display one or more small areas 
of subepithelial biotin staining (Figure 5A) whose total length averages 390 ± 281µm 
(Figure 5E).  In contrast, tracheas with visible regions of epithelial denudation typically 
display one large area of subepithelial biotin staining (Figure 5B) whose total length 
averages 2411 ± 1070 µm (Figure 5E). The length of subepithelial staining in individual 
mice closely correlates with the length of associated epithelial denudation (Figure 5F, r = 
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0.920, p < 0.0001).  Moreover, the length of this subepithelial staining, when measured 
from the center of epithelial denudation, either equals or slightly exceeds the length of 
epithelial denudation (Figure 5G). These results demonstrate that Sulfo-NHS-biotin 
staining accurately labels the extent and position of epithelial denudation. 
To determine if obliterative airway lesions arise from areas of epithelial 
denudation in individual mice, a separate study was performed in which mice were 
exposed as before to low or high dose Cl2, and then administered Sulfo-NHS-Biotin after 
4 days.  In these studies, however, the tracheas were harvested 3 days later rather than at 
4 hours to allow time for repair or lesion formation.  In these samples, surface staining of 
airway epithelial cells was not detected, probably due to membrane turnover of labeled 
live cells, but areas of subepithelial staining remained visible.  No intraluminal lesions 
were found in sections that contained less than 300µm of subepithelial staining, 
suggesting that the development of such lesions requires a certain amount of epithelial 
denudation (Figure 5H).  In contrast, all sections with >300µm of subepithelial staining 
contained intraluminal lesions.  In individual mice, the length of tracheal wall covered 
by intraluminal lesions closely correlates with the length of subepithelial staining 
(Figure 5 I, r = 0.995, p<0.0001).  Lesions, when measured from the center of biotin 
staining, typically equal or slightly exceed the length of the associated biotin stain 
(Figure 5 J). These findings demonstrate that intraluminal lesions arise from areas of 
epithelial denudation and suggest that the size of intraluminal lesions is determined by 
the extent of epithelial denudation. 
We also graphed the data points in Figures 5E and H in a manner that reflects the 
exposure group from which each data point was generated (Figure 6).  Data points 
representing short lengths of biotin staining and associated with no visible denudation 
or lesions were primarily generated after exposure to low Cl2.  In contrast, data points 
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representing long lengths of biotin staining and associated with visible denudation or 
lesions were primarily generated after exposure to high Cl2. 
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Figure 5: Tracheal blockages originate from areas of denuded epithelium. 
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Mice were exposed to low or high dose Cl2 then intranasally given the labeling agent 
Sulfo-NHS-biotin 4 days post exposure.  (A and B) Immunofluorescent staining of e-
cadherin and biotin 4 hours after administration of NHS-biotin in mice that were 
exposed to low or high dose Cl2.  Images are representative of multiple tracheas; low Cl2 
n=5 and high Cl2 n=10 (2 examples are shown in B).  (C and D) Immunofluorescent 
staining of e-cadherin and biotin 3 days after biotin labeling (7 days post exposure to 
low or high dose Cl2).  Images are representative of multiple tracheas; low Cl2 n=3 and 
high Cl2 n=7 (2 examples are shown in D).  Scale bar is 200µm.  White dots mark regions 
of subepithelial biotin staining.  The lengths of these regions was measured along the 
basement membrane (b.m.) for quantitation.  (E) The length of subepithelial biotin 
staining in areas with or without visible denudation.   n=15 tracheas ; ***p<.0001 by 
student t test.  (F) Correlation between length of biotin staining and the length of 
epithelial denudation; r=.920, p<.0001.  n=10 tracheas.  (G) The length of biotin staining 
in areas of denuded epithelium was measured from the center of the denuded area 
outward in each direction.  For each data point, the length is an average of the left and 
right extensions.  n=10 tracheas.  (H) The length of subepithelial biotin staining in areas 
with or without visible lesions.  n=10 tracheas; ***p<.0001 by student t test. (I) 
Correlation between length of biotin staining and the length of luminal lesions; r=.995, 
p<.0001.  n=6 tracheas.  (J) The length of lesions measured from the center of the 
associated biotin staining outward in each direction. For each data point, the length is an 
average of the left and right extensions.  n=6 tracheas. 
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Figure 6: Length of NHS biotin staining by Cl2 exposure group. 
The length of subepithelial biotin staining in areas with or without visible denudation; 
low Cl2 n=5 and high Cl2 n=10.  (B) The length of subepithelial biotin staining in areas 
with or without visible lesion; low Cl2 n=3 and high Cl2 n=7.
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2.3.5 Inflammatory cell infiltration precedes airway intraluminal 
fibrosis 
To better define the specific cellular events that are associated with the 
development of intraluminal lesions, we examined the time course of inflammation, 
collagen production, and vascularization in mice exposed to 350ppm Cl2.  By day 2 after 
exposure, CD11b+ cells, consisting of both neutrophils and macrophages, begin to 
infiltrate the dead epithelium (Figure 7A, B).  By day 5, infiltration by CD11b+ cells is 
substantial (Figure 7G), with macrophages (arrowheads) and neutrophils (small arrows) 
being the predominant cell types (Figure 7E, F).  By day 7, myeloid cell infiltrates 
decrease (Figure 7 I-K) but in many cases reappear when mice develop terminal 
respiratory distress on or around day 9 (Figure 7 M-O).  Higher magnification images of 
CD11b and collagen I staining are provided in Figure 8. 
To quantify these inflammatory cell infiltrates, whole tracheas from mice 
exposed to low or high dose Cl2 were digested into single cell suspensions, then 
subjected to flow cytometric analysis.  In mice exposed to low dose Cl2, numbers of total 
tracheal cells and monocytes/macrophages (CD11b+Ly6G-) are significantly increased at 
day 5 only, with no increase in neutrophils (Figure 7 Q-S).  In mice exposed to high dose 
Cl2, numbers of total tracheal cells and monocytes/macrophages are significantly 
increased at all time points and the number of neutrophils significantly increased on 
days 3 and 7 (Figure 7 Q-S).  These findings demonstrate that inflammatory cell 
infiltration, especially of monocytes/macrophages precedes the development of 
intraluminal lesions, which are typically observed on day 7 after Cl2 exposure. 
At the time when infiltration of monocytes/macrophages is peaking, around day 
5 post-exposure, collagen-producing cells begin to infiltrate the cellular mass (Figure 7 
H, white arrows).  Once this begins, the deposition of collagen producing fibroblasts and 
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connective tissue within the airway lesion increases rapidly (Figure 7 F,J,N and H,L,P).  
Consequently, tracheas can progress from being totally patent to near totally occluded 
over a period of 4 days (Figure 7 E,I,M).  
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Figure 7: Loss of epithelial integrity results in inflammatory cell infiltration, 
mesenchyme infiltration, and collagen deposition.  
H&E staining of tracheal epithelium 2 days after exposure to high dose Cl2 (A). 
Immunofluorescent staining for CD11b (red) in a similar day 2 tissue section (B).  In A 
and B, scale bar is 25µm.  Immunofluorescent staining of either CD11b (red) or collagen I 
(green) in a control tracheal section and sections harvested on day 5, 7 and 9 after high 
dose Cl2; CD11b (C,G,K,O respectively); collagen I (D,H,L,P respectively); scale bar is 
200µm.  In H, white arrows denote collagen 1+ cells infiltrating the lumen.  H&E staining 
of tracheal sections harvested on days 5, 7 and 9 after high dose Cl2 (E,I,M respectively; 
scale bar is 200µm), (magnified images F,J,N respectively; scale bar is 25µm)  In F, 
arrowheads denote macrophages while small arrows denote neutrophils.  All tissue 
sections are representative of 5-6 tracheas at each time.  Asterisks denote the lumen.  
Using flow cytrometry, total cells (Q), non-neutrophil CD11b+ cells (R), and neutrophils 
(S) were quantified from tracheal digests from mice exposed to FA, low, or high dose 
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Cl2.  Bars represent mean ± SD for 5-8 mice per group. *p<0.05; ** p<0.005;***p<.0001 in 
comparison to FA by student t test. ^p<0.05; ^^ p<0.005 in comparison to day-matched 
low dose Cl2 by student’s t test. 
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Figure 8: CD11b+ inflammatory infiltrates and collagen I+ infiltrates. 
Magnified images of immunofluorescent staining for either CD11b (red) or collagen I 
(green) in sections harvested on day 5, 7 and 9 after high dose Cl2; scale bars are 50µm. 
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2.3.6 Vascularization of obliterative airway lesions is a late event 
To determine if vascularization plays a significant role in the development of 
obliterative airway lesions, we performed immunohistochemistry for the endothelial cell 
(EC) marker PECAM-1 on tissue sections over the course of lesion development.  Prior 
to exposure, tracheal blood vessels lie just below the basal lamina (Figure 9A).  EC 
remain in this position though day 5 post Cl2 exposure (Figure 9 B,C).  By day 7, EC 
begin to penetrate the basal lamina into the developing obliterative lesions (Figure 9 D,E 
arrows).  This corresponds to the time of rapidly increasing cellularity within 
obliterative lesions.  By day 9, obliterative airway lesions are highly vascularized (Figure 
9F).  These findings suggest that vascularization does not play a role in the initiation of 
obliterative airway lesions.  
 38 
 
Figure 9: Vascularization of tracheal blockages. 
Immunofluorescent staining of endothelial cells (PECAM-1, green) in an uninjured 
trachea and tracheas harvested 3 (B), 5 (C), 7 (D,E), and 9 (F) days after exposure to high 
dose Cl2. Whites dots denote the basal lamina.  White arrows denote endothelial sprouts 
into the lumen.  Asterisks denote the lumen.  Tissue sections are representative of 5-6 
tracheas at each time.  Top panel, scale bar is 50µm. Bottom panel, scale bar is 200µm. 
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2.4 Discussion 
BO is a debilitating and potentially lethal disease resulting from the narrowing of 
the airways by fibrosis and inflammation.  The pathogenesis of BO is not clearly 
understood but may involve immune components, tissue ischemia, and epithelial 
damage [38, 63].  The majority of BO cases, animal and human, include epithelial 
damage, but not all cases of epithelial damage result in BO.  Here, we find that loss of 
basal cells is closely associated with the development of obliterative airway lesions in a 
model of acute toxin-induced airway injury.  This conclusion is based on several 
findings.  First, we demonstrate that the extent of acute injury to luminal epithelial cells 
does not correlate with the development of obliterative airway lesions.  Second, we find 
that development of such lesions occurs only under conditions and in areas in which 
basal cells are eliminated.  Third, we find that loss of basal cells is closely associated with 
a failure to re-epithelialize regions of epithelial denudation.  Fourth, we find that 
obliterative airway lesions arise only at sites of epithelial denudation and that the size of 
such developing lesions closely correlates with the extent of epithelial denudation.  To 
our knowledge, this is the first demonstration that intraluminal fibrotic lesions arise 
specifically at sites of epithelial denudation.  Taken together, our findings suggest a clear 
mechanism by which loss of basal cells leads to airway intraluminal fibrosis.  This 
mechanism is consistent with human pathological studies in which obliterative airway 
lesions appear to arise from areas of epithelial denudation[63]. 
Although our findings demonstrate strong correlations among basal cell loss, 
persistent regions of epithelial denudation, and the development of airway intraluminal 
fibrosis, they do not directly prove that basal cell loss is the cause of airway intraluminal 
fibrosis.  Such proof will likely require the targeted preservation or elimination of basal 
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cells in an animal model.  However, several other associative studies have been 
performed that support our overall conclusion.  It is known that only some toxic 
chemical exposures lead to the development of BO.  Our findings would suggest that the 
ability of individual chemicals to cause BO is directly related to their effects on basal 
cells.  Although data on the toxicity of specific chemicals toward basal cells is limited, 
the studies that are available support this conclusion.  In animal models, chemicals such 
as naphthalene, nolidocanol, and SO2 do not cause basal cell loss and do not cause 
airway intraluminal fibrosis [67].  In contrast, exposures to diacetyl and sulphur 
mustard, which are known to cause BO, have been shown to cause basal cell depletion 
[68, 69].  For any given chemical, there will also be a dosage effect, as demonstrated by 
our comparison of Cl2 dosages.  In addition, a recent study comparing Cl2-induced lung 
injury in FVB/NJ and A/J mice found that reduced epithelial repair and increased 
airway fibrosis were associated with a reduced number of resident basal cells at 
baseline[64, 70].  Taken together, our findings and previous reports demonstrate a clear 
association between basal cell loss and the development of obliterative airway lesions.   
According to our model, loss of basal cells does not directly stimulate obliterative 
airway lesion formation.  Rather, it is the failure of re-epithelialization and the 
consequent prolonged presence of regions of complete epithelial denudation that 
stimulates an intraluminal fibrotic response.  This view is consistent with previous 
studies in which epithelial denudation induced by chronic depletion of mature epithelial 
cells results in the development of BO-like fibrotic lesions [38, 39].  After chronic Clara 
cell depletion, intrabronchiolar fibrotic lesions only arise in areas of complete epithelial 
denudation, whereas peribronchiolar fibrosis arises in areas that maintain epithelial 
intergrity despite persistent epithelial injury.  Pathologically, the intra- and peri-
bronchiolar fibrosis are similar to human proliferative and constrictive BO, respectively.  
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These observations suggest that the development of proliferative versus constrictive BO 
may depend on the extent and timing of epithelial injury.  It is also possible that 
proliferative BO can advance to constrictive BO.  In a nitric acid-induced rat model of 
BO, proliferative lesions were observed after the first week of injury, followed later by 
the occurrence of constrictive BO [71].  We were unable to address the possibility of a 
transition from one pathology to another in our model, as all mice that survived high 
dose Cl2 exposure displayed fully re-epithelialzed tracheas 2-3 weeks post injury with no 
evidence of fibrosis (data not shown).  We assume these mice retained enough surviving 
basal cells to repair normally and avoid proliferative BO initiation. 
Although our findings apply directly only to proximal airway regions that 
contain basal cells, it is likely that depletion of other types of epithelial progenitor cells 
in distal airways also leads to intraluminal fibrotic lesions.  Human pathological studies 
demonstrate that such lesions arise by connective tissue penetrating areas of epithelial 
denudation [63].  Several types of distal airway and alveolar epithelial progenitor cells 
have been described that are distinct from basal cells [72].  It would be of interest to 
determine if such cells are depleted by stimuli that lead to distal airway or alveolar 
intraluminal fibrosis.  This would include exposure to chemicals such as phosgene and 
chloropicrin that preferentially target the distal lung.  It would also include non-toxin-
related causes of BO.  For example, in lung transplantation-induced BO, it is possible 
that immune-mediated epithelial progenitor cell death contributes to aberrant repair 
processes and fibrosis.  Similarly, the tissue ischemia that is associated with lung 
transplantation may be extensive enough to eliminate epithelial progenitor cells. 
The model of Cl2-induced airway injury we describe causes the reproducible 
ablation of basal cells followed by the rapid development of obliterative airway lesions.  
Relative to other models of BO, this model offers several advantages.  It is relatively 
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simple, requires no surgery, is highly reproducible, and results in the near total 
occlusion of airways within 10-12 days.  Exposure of mice to high dose Cl2 induces a 
well-demarcated series of pathological changes that will allow a more detailed analysis 
of the individual cellular and molecular events that lead from basal cell loss to airway 
occlusion.  Because this model uses C57BL/6 mice, it is readily amenable to analysis 
using the large number of genetically altered mouse strains available on this 
background.  We anticipate that this model will prove useful in elucidating the 
pathophysiology of proliferative BO and in the identification of potential therapeutics 
for this disease.  
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3. In vivo evaluation of anti-angiogenic therapeutics in Cl2-
induced bronchiolitis obliterans 
3.1 Introduction 
Currently, there are no therapeutics for the treatment of constrictive BO and 
steroid-resistant proliferative BO. A major goal of our research is to identify and 
evaluate therapeutics using our previously characterized Cl2-induced BO model. We 
identified a well-demarcated series of pathological changes in the airways (e.g. epithelial 
denudation, inflammatory cell infiltration, fibroblast infiltration and collagen deposition, 
and in-growth of blood vessels). The necessity of each pathological change in the 
progression of BO is not understood. In this chapter, we present our preliminary data on 
the efficacy of anti-angiogenic therapeutics in the prevention of Cl2-induced blockage 
formation.  
Neovascularization is a common finding in human instances and animal models 
of BO.  In a heterotrophic trachea transplantation model of BO, a 3-fold increase in vessel 
counts were observed in allografts compared to syngenic grafts 21 days post 
transplantation [73]. Additionally, lung biopsies of oleic acid-induced BO in dogs 
showed polys of variable size and shape in the bronchioles, most of which were 
neovascularized [45]. In humans, BO-affected lung tissue showed evidence of 
fibrovascular tissue in the airway [73].  
Vascular endothelial growth factors (VEGFs) and their receptors, VEGFR-1 and 
VEGFR-2, are major regulators of angiogenesis [74-76]. VEGF-A is a shared ligand for 
VEGFR-1 and VEGFR-2, but the receptors have opposing effects. VEGFR-2 is considered 
the major regulator of the cellular effects of VEGF-A, including angiogenesis, and can 
additionally bind VEGF-E, -C, and –D. Conversely, VEGFR-1 is thought to act as a 
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negative regulator of VEGFR-2 through its ability to binds VEGF-A with much higher 
affinity, effectively sequestering the ligand away from VEGFR-2. VEGFR-1 also binds 
VEGF-B, PLGF-1 and -2.  The VEGF receptors are primarily expressed on endothelial 
cells but are also expressed on many other cells types including, but not limited to, 
macrophages, monocytes and platelets[77, 78]. 
Therapeutically targeting the VEGF pathway has resulted in successful inhibition 
of neovascularization [79]. In particular, cancer research has taken advantage of 
inhibiting this pathway, since neovascularization is a major mechanism supporting 
tumor growth.  One therapeutic strategy uses adenoviral production of soluble VEGFR-
1 to increase receptor levels in the blood. Due to its high affinity, VEGFR-1 sequesters 
the natural ligands away from the pro-angiogenic VEGFR-2.  This therapy resulted in 
80% inhibition of tumor growth in a murine cancer model [80]. A different anti-
angiogenic therapeutic strategy used the anti-murine VEGFR-2 antibody, DC101, to 
prevent the receptor’s ability to bind ligand, subsequently blocking VEGFR-2 signaling.  
Use of DC101 in a murine tumor model also resulted in significantly decreased tumor 
growth and metastasis [81].   
We hypothesized that blockage growth in our Cl2-induced BO model may 
require neovascularization to supply nutrients to the granulation tissue and that cutting 
off that supply via anti-angiogenic therapies could mitigate blockage growth and protect 
mice from lethal airway obstruction. Here we tested the two anti-angiogenic therapies 
discussed above in our BO model. 
3.2 Materials and methods 
Chlorine exposures. Exposures were conducted as described in chapter 2 
methods. 
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VEGFR-1 adenovirus. Adenoviral vectors were kindly provided by Dr. 
Christopher Kontos (Department of Medicine/Cardiology, Duke University).  The 
vectors were first-generation E1-deleted replication-defective vectors made by Ad-Easy 
system (Agilent Technologies, Santa Clara, CO). Gene expression of the protein/peptide 
of interest was driven by human cytomegalovirus immediate/early promoter. Empty 
adenoviral vector was used as control (Ad-control). Approximately 2.5 to 7.5 x 109 pfu of 
adneo-VEGFR-1 or empty virus was injected into mice via tail vein. 
DC101. DC101 was kindly provided by Dr. Andrew Nixon (Department of 
Medicine/Medical Oncology, Duke University). DC101 was produced from hybridoma 
cells and concentrated in media as previously described [82].  Starting 24 hours post Cl2 
exposure, mice received an i.p. injection of 800ug DC101 then subsequent i.p. injections 
of 400ug DC101 on days 4, 6, 7, and 8. 
Soluble VEGFR-1 detection. We determined plasma soluble VEGFR-1 (R&D 
Systems, Minneapolis, MN) using commercial ELISA kits and according to the 
manufacturer's specifications. 
3.3 Results 
3.3.1 A VEGFR-1 ligand trap does not prevent BO blockage formation  
To test if inhibition of the VEGF signaling pathway prevents blockage formation 
we used adenovirus overexpression of soluble VEGFR-1 to sequester natural ligands 
from VEGFR-2.  Three days prior to chemical injury, we i.t. administered an adenovirus 
expressing an empty vector (ad-control) or soluble VEGFR-1 (ad-VEGFR-1). Others have 
demonstrated that this adenovirus preferentially infects liver hepatocytes and produces 
circulating levels of VEGFR-1 that are elevated for up to 2 weeks after treatment [80, 83]. 
Mice were then nose-only exposed to high Cl2 for 30 minutes.  Seven days post exposure, 
mice were sacrificed for blood and trachea harvest. Figure 10A diagrams the 
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experimental timeline. Serum levels of soluble VEGFR-1 were quantified, allowing us to 
identify positive expressers (Figure 10B). Mice with expression < 3.0 ng/ml were not 
included in our analysis since their expression most likely does not reach therapeutic 
levels. The harvested tracheas were scored by gross observation for the presence or 
absence of blockage (Figure 10C). There is no significant difference between the ad-
control group (75% blockage positive) and the ad-VEGFR-1 group (80% blockage 
positive). Vessel density was not counted. Anecdotally, blood vessels were grossly 
visible in blockages of both groups, and blockage sizes did not differ among groups. 
Despite high levels of circulating soluble VEGFR-1, blockage formation was not 
prevented after high dose Cl2-induced injury. 
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Figure 10: Overexpression of soluble VEGFR-1 by adenovirus does not prevent BO 
lesions  
A) Experimental timeline of adenovirus administration, Cl2 exposures and tissue 
harvest. B) Serum levels of soluble VEGFR-1 in individual mice 7 days post Cl2 exposure 
(350ppm) and 9 days post intravenous injection with an adenovirus encoding VEGFR-1 
(Ad-VEGFR-1, n=14) or control (Ad-control, n=8). C) Tracheas were harvested on day 7 
post Cl2 exposure then grossly examined and categorized based on the presence or 
absence of blockage formation in the airways. The categorization of one trachea was 
inconclusive. For, the control group n=8. For the Ad-VEGFR-1, n=10; the Ad-VEGFR-1 
mice #1, 2, 3, and 14 in panel B were removed from blockage analysis due to their low 
levels of circulatory soluble VEGFR-1. 
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3.3.2 An anti-VEGFR-2 blockade does not prevent lethal BO airway 
obstruction 
We used an alternative therapeutic strategy to inhibit VEGFR-2 signaling. The 
anti-murine VEGFR-2 antibody, DC101, interrupts the receptor’s ability to bind ligand 
and prevents VEGFR-2 signaling. Mice were exposed to 30 minutes of high Cl2. Then 
mice were either given PBS or 800ug of DC101 i.p. starting 24 hours post injury, then 
given 400ug of DC101 on days 4, 6, 7, and 8. This dose was comparable to a previous 
therapeutic regimen reported to significantly inhibit tumor growth in a murine cancer 
model [81]. Mice were monitored for two weeks, during which they were euthanized 
upon development of excessive labored breathing. The tracheas of euthanized mice were 
examined and scored by gross observation for the presence or absence of blockage. All 
tracheas of mice requiring euthanasia had obstructive BO blockages (data not shown).  
There was no statistical difference in survival between PBS and DC101-treated groups 
(Figure 11). 
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Figure 11: DC101 A VEGFR-2 specific monoclonal antibody, DC 101, does not prevent 
the development of lethal BO 
Mice were exposed to Cl2 (350ppm). Mice were given i.p. administrations of DC 101; 
800ug on day 1, then 400ug on days 4, 6, 7, and 8. The control group was given PBS. DC 
101 group, n=8; control group, n=9. The difference in survival curves was not significant; 
p=.1607 by log-rank test. 
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3.4 Discussion 
Our findings suggest that inhibition of the VEGFR pathway, primarily mediated 
by VEGFR-2, does not protect mice from chemical-induced BO. The data obtained here 
were preliminary; therefore, we cannot make this claim with certainty. There are two 
major limitations in our study. 1) We did not validate the activation of the VEGFR-2 
pathway in our injured tissue. Based on histological evidence of neovascularization, we 
assumed that VEGFR-2 was active. 2) We did not validate that soluble VEGFR-1 or 
DC101 was present at levels sufficient to inhibit VEGFR-2 activation. However, we 
believe that the inability of two separate VEGFR-2 inhibiting techniques to protect or 
alter the course of BO development strongly indicates the dispensable nature of the 
VEGFR-2 pathway in the development of BO. 
Several studies corroborate our findings that VEGFR is dispensable for 
neovascularization. A study of human bronchoalveolar lavage fluid (BALF) from lung 
transplant patients showed no correlation between VEGF concentrations and incidents 
of BO [84].  Additionally, a separate study of human BALF from BO positive transplant 
patients demonstrated that neutralization of VEGF in the BALF did not reduce 
angiogenic responses measured in an ex vivo BALF-stimulated angiogenesis assay [73]. 
However, neutralization of CXCR2 ligands using an anti-CXCR2 antibody antagonist 
inhibited the antigenic response by more that 60% of the non-neutralized BALF controls. 
These findings urged us to consider alternative pathways of neovascularization. 
Growing evidence implicates CXCR2 and its ligands as a biological axis of 
vascular remodeling in several diseases including, cancer, pulmonary fibrosis and BO. 
[85-89]. More importantly, Belperio et al. demonstrated greatly increased 
immunohistological staining for CXCR2 in human BO biopsies that colocalized to 
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remodeled vasculature. Subsequently, they demonstrated that a therapeutic-regimen of 
anti-CXCR2 antibody significantly reduced the severity of disease in a murine 
heterotrophic transplant model of BO. Specifically, they observed decreases in early 
neutrophil recruitment, reduced angiogenic activity in an ex vivo corneal micropocket 
assay of angiogenesis, and overall attenuation of BO severity (scored as an average of 
airway lining epithelial loss, leukocyte infiltration, extracellular matrix deposition, and 
luminal obliteration)[73]. 
The same mechanism of neovasculariztion may occur in our chemical-induced 
BO model. It would be interesting to evaluate the effect of CXCR2 neutralization in our 
BO model since there are several major differences between our model and the 
herterophic BO model (e.g. allorejection independent vs. dependent, location: 
functioning airway vs. subcutaneous implantation, non-surgical vs. surgical technique). 
In chapter 5, we will continue our discussion on the potential involvement of the CXCR2 
biological axis in our BO model with additional insight gleaned from microarray 
analysis of BO lesions. 
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4. In vivo evaluation of anti­inflammatory therapies in Cl2­
induced bronchiolitis obliterans 
4.1 Introduction 
As previously mentioned, a major goal of our research is to identify and evaluate 
therapeutics using our Cl2-induced model of BO. In chapter 3, we targeted 
neovascularization, one of several pathological changes in the airways (e.g. epithelial 
denudation, inflammatory cell infiltration, fibroblast infiltration and collagen deposition, 
and in-growth of blood vessels). In the present chapter, we will target inflammation; 
specifically, we will prevent inducible nitric oxide synthase (NOS2)-mediated 
inflammation and determine the therapeutic efficacy of NOS2 inhibition in our model. 
An indirect mechanism implicated in Cl2-induced respiratory injury is the 
excessive production of nitric oxide (NO), leading to increased and persistent oxidative 
burden. Three nitric oxide synthases catalyze the release of nitric oxide from L-arginine. 
These include neuronal NOS, epithelial NOS, and inducible NOS (NOS2).  Expression of 
NOS2 is initiated by inflammation [90]. NOS2 is highly expressed in pulmonary 
macrophages, cells that respond to inflammation by generating effector molecules such 
as tumor necrosis factor alpha (TNF-α) and NO [91, 92]. Excessive levels of NO can be 
tissue-damaging. Studies suggest that, after chemical inhalation, NO produced by NOS2 
interacts with superoxide to form peroxynitrite, which can cause tissue damage directly 
or lead to DNA strand breakage [93].  DNA damage triggers the activation of poly-ADP 
ribose polymerase, a DNA repair enzyme, which depletes cellular ATP, leading to 
necrotic cell death [94-97].  Excessive NO may also contribute to lung injury by 
abolishing the pulmonary vasoconstriction reflex to hypoxia [98]. A previous study 
showed that pharmacological inhibition of NOS2 prior to Cl2 exposure reduces 
subsequent Cl2-induced increases in AHR, however fibrotic airway changes were not 
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assessed [99]. It is unknown whether NOS2-produced NO contributes to fibrotic 
pathological changes resulting from Cl2-exposure. In bleomycin-induced pulmonary 
fibrosis, airway NOS2 expression levels increase and pharmacological inhibition of 
NOS2 reduces disease severity and improves survival of bleomycin-challenged mice 
[100, 101]. This implicates NOS2 as a mediator of fibrosis. In this chapter, we sought to 
determine whether Cl2-induced BO is mediated by NOS2 and to determine if NOS2 
inhibitors, when used therapeutically, can prevent or delay lethal airway obstruction. 
Additionally, we sought to test the efficacy of steroid therapy in our model. Not 
only are steroids potent suppressors of inflammation, clinical findings demonstrate that 
most cases of proliferative BO respond favorably to steroid treatment [24]. 
Histopathologically our model of Cl2-incuded BO is more similar to proliferative than 
constrictive BO, so we hypothesized that use of steroids would be protective in our 
model. However, aggressive forms of proliferative BO exist that are not responsive to 
steroids. Additionally, constrictive BO responds poorly to steroid treatment and is 
considered irreversible. We evaluated the effect of steroid therapy in our model. 
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4.2 Materials and methods 
Mice. C57BL/6 were purchased from Charles River Laboratories (Wilmington, 
MA) and Nos2 null mice (stock # 002596) were purchased from Jackson Laboratory (Bar 
Harbor, ME). The majority of our experiments used 10-12 week-old male mice. All 
animal experiments were conducted in accordance with National Institutes of Health 
guidelines and protocols approved by the Animal Care and Use Committee at Duke 
University. 
Chlorine Exposures. Exposures were conducted as described in chapter 2 
methods. 
1400W administration. The NOS2 inhibitor 1400W (N- [[3- 
(aminomethyl)phenyl]methyl]- ethanimidamide, dihydrochloride ([2-[(1-iminoethyl) 
amino]ethyl]-l-homocysteine)) was purchased from Cayman Chemical Company (Ann 
Arbor, Michigan, USA).  Prior to use, the compound was dissolved in PBS at 0.5 mg/ml 
(2.0 mM concentration).  Starting 3 hours post chemical exposure and then daily for 7 
days, mice received aerosolized drug or placebo treatments using the nose-only 
inhalation chamber.  The duration of daily aerosol treatment was 30 minutes.  
Statistics. The comparison between survival curves was performed with the log-
rank test using GraphPad Prism software. 
Solu-medrol. Starting 24 hours post Cl2 exposure, mice received daily i.p. 
injections of .1mg solu-medrol, also known as methylprednisolone sodium succinate, 
(Pfizer, New York City, NY) for 6 days. 
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4.3 Results 
4.3.1 Therapeutic administration of NOS2 inhibitors does not prevent 
lethal BO airway obstruction 
To determine if pharmacologic inhibition of NOS2 can provide a benefit when 
administered therapeutically, we examined the survival of Cl2-exposed mice treated 
with the small molecule NOS2 inhibitor 1400W.  Three hours post Cl2 exposure mice 
were treated with an aerosol of 1.0 mM 1400W for 30 minutes; this therapy was 
repeated daily for 9 days. Anecdotally, both groups of mice demonstrated similar 
behavior patterns. There was no difference in survival between treated and untreated 
groups; both groups had 50% survival at day 14 (Figure 12A).  
4.3.2 Nos2-deficient mice are not resistant to lethal BO airway 
obstruction 
In the above experiment, we did not validate the efficiency of aerosol delivery of 
NOS2 inhibitors to inhibit NOS2 activity in the lung. It is possible that the concentration 
of the inhibitor delivered into the airway was not sufficient for NOS2 inhibition. To 
overcome this challenge, we repeated the survival experiment using Nos2-deficient mice. 
There was no difference in survival between wild-type (WT) and Nos2-deficient mice 
(Figure 12B). These findings suggested that NOS2 does not play a role in the 
pathogenesis of BO in our model. 
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Figure 12: Pharmacological inhibition of NOS2 with 1400W does not prevent the 
development of lethal BO  
A) Mice were exposed to Cl2 (350ppm) then given aerosolized PBS or 1400W (.5mg/ml) 
starting 4 hrs post exposure and then once daily for 9 days; n=6 for each group. The 
difference in survival curves was not significant; p=.9086 by log-rank test. B) WT and 
Nos2-deficient mice were exposed to Cl2 (350ppm); WT group, n=9; Nos2-deficient 
group, n=5. The difference in survival curves was not significant; p=.4847 by log-rank 
test. 
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4.3.3 Steroid Treatment does not prevent BO blockage formation 
Since a large proportion of human proliferative BO can be resolved with steroid 
treatment, we determined if steroid treatment could resolve blockage formation in our 
model. Mice were exposed to 30 minutes of high Cl2. Subsequently mice were either 
given PBS or 0.1mg of solu-medrol i.p. starting 24 hours post injury and then once daily. 
Seven days post exposure, tracheas were harvested then scored by gross observation for 
the presence or absence of blockage (Figure 13). There is no statistical difference between 
the control PBS group (60% blockage positive) and the solu-medrol group (100% 
blockage positive). The deviation of both groups from our historical average mortality, 
~80%, is most likely due to normal variations that were exaggerated by the small 
number of mice in each group, n=5. 
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Figure 13: Steroid treatment does not prevent BO lesions 
Mice were exposed to Cl2 (350ppm) then given i.p. administrations of solu-medrol (.1mg 
per mouse) or PBS everyday starting 24 hours post exposure; n=5 for each group. 
Tracheas were harvested on day seven post exposure then grossly examined and 
categorized based on the presence or absence of blockage formation in the airways. 
 59 
 
4.4 Discussion 
In this chapter, we demonstrated that NOS2 is dispensable for the development 
of lethal airway obstruction seen after Cl2 inhalation. Our findings were unexpected 
considering there is evidence that NOS2 inhibition is effective at reducing lung injury 
after exposure to other toxins and in other types of lung injury.  For example, sheep 
treated with a NOS2 inhibitor after smoke inhalation demonstrate significantly 
decreased respiratory dysfunction and inflammation relative to vehicle-treated controls 
[102].  Bleomycin-induced lung injury and mortality are reduced in Nos2–deficient mice 
or mice treated with an NOS2 inhibitor [101].  Additionally, NOS2 inhibition preserves 
airway and pulmonary epithelial barrier function in endotoxemic mice [103].  Clearly, 
NOS2 contributes differentially to the multiple pathologies that can arise after Cl2 injury 
(e.g. acute lung injury, reactive airway dysfunction syndrome, and fibrosis) and other 
pulmonary diseases. One possible explanation for our observations is that NOS2-driven 
pathology may depend on the enzyme’s ability to generate biologically significant 
increases in oxidative burden. The same mechanism may not be applicable in our model 
since the direct mechanism of Cl2 injury is excessive oxidization. NOS2-generated 
oxidative injury may not increase the oxidative burden already inflicted by Cl2 and, 
therefore, is not biologically significant. However, this is a very simplistic explanation 
for the effects of a complex molecule, NO, that induces a wide range of physiologic 
effects depending on concentration and effected cell types [104]. From our data, we 
conclude that NOS2-generated NO is not a critical regulator of intraluminal fibrosis after 
Cl2 injury.   
Steroid-treatment was ineffective at preventing BO in our model. Histologically, 
the fibrotic blockages that developed after Cl2 injury resembled proliferative BO, 
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however, they did not respond to steroid treatment in a similar manner.  65-80% of 
human proliferative BO resolves after corticosteroid treatment [24]. Our findings may 
indicate that our model represents the 20-35% of proliferative BO that does not respond 
to treatment. Currently, the mechanism of action for corticosteroid protection is 
unknown. One possible mechanism is that steroid treatment prevents additional 
epithelium injury by suppressing epithelial- and leukocyte-induced inflammation. The 
same mechanism may not be applicable in our model since the majority of epithelial cell 
damage occurs during and immediately after chemical exposure. Our findings suggest 
that steroids are not effective in treating the fibrotic processes that contribute to BO. 
However, a major limitation of our experiment was that we did not confirm that steroid-
treatment actually reduced inflammation in our model.  There is the possibility that the 
time between injury and airway obstruction may be too short for steroid-treatment to be 
effective. In our future research we intend to continue in vivo evaluation of 
inflammation-targeted therapeutics for the prevention of BO. 
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5. Identification of potential molecular mediators of 
bronchiolitis obliterans using bioinformatics 
5.1 Introduction 
Our selection of therapeutic targets above was solely based on histopathologic 
findings in the development of bronchiolitis obliterans. In vivo modulation of those 
targets with previously described therapeutic regimens did not grossly alter the 
progression of fibrosis. Therefore, we used microarray expression profiling of injured 
tracheal tissue to identify potential molecules and signaling pathways that regulate BO 
progression. Comparison of gene expression profiles after exposure to non-BO- and BO-
inducing toxic gas inhalation allowed us to differentiate up-regulation of genes 
associated with normal epithelial injury/repair versus upregulation of genes specific to 
BO. Using cutting-edge pathway analysis software, we identified enriched biological 
pathways specific to BO-development and even predict upstream regulators of the 
disease process. Our intentions are that this rigorous analysis will result in the 
identification of BO-specific therapeutic targets with the potential to resolve or mitigate 
airway injury after Cl2 gas inhalation injury. We will discuss the merits of the potential 
therapeutic targets that were identified based on current literature. 
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5.2 Materials and methods 
Chemical exposures. Cl2 exposures were conducted as described in chapter 2 
methods. For SO2 exposures, 8 week old female mice were placed in individual 
compartments of a chamber and whole body exposed to 500 ppm SO2 in air for 3 hours, 
as previously described (Rawlins, 2006).  
Gene expression profiling by microarray. Tracheas were dissected and cleaned 
of surrounding connective tissue. Each trachea was then cut into one small cylindrical 
segment by trimming away the bronchioles just above the bronchiole bifurcation and 
trimming away the proximal airways at the third or fourth tracheal ring.  The tissue 
segment was immediately frozen in RLT buffer (RNeasy Mini Kit; Qiagen, Valencia, CA) 
and later bead homogenized. RNA was immediately extracted using the RNeasy Mini 
Kit. RNA was submitted to the Duke University microarray core facility for microarray 
analysis. RNA quality was checked with a 2100 Bioanalyzer (Agilent Technologies). 
cDNA was amplified, then Cy3-labelled cDNA was hybridized to a Whole Mouse 
Genome 4×44K v2 array (Agilent Technologies). Microarray cDNA was amplified from 
20 ng total RNA using Ovation Pico WTA system V2 (NuGEN Technologies, San Carlos, 
CA, USA). Cy3-labelled cDNA was hybridized to a Whole Mouse Genome 4×44K v2 
array (Agilent Technologies).  
Microarray analysis. Data analysis was performed using the Partek Genomics 
Suite (Saint Louis, MO). First, the raw data were imported and normalized. 
Subsequently ANOVA statistical analysis was performed on the entire dataset searching 
for significant differences between exposure groups (filtered air, SO2, low Cl2, high Cl2). 
Subsequently, significantly upregulated or downregulated genes were identified based 
on fold changes <-3 or >3 and a p-value of <0.01 . Hierarchical clustering analysis and 
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principal components analysis were performed within the software suite. To investigate 
functional characteristics as well as upstream regulators of specific gene lists, we used 
Ingenuity Pathway Analysis (IPA) (Ingenuity Systems, Redwood City, CA).  IPA 
mapped genes and calculated P values (Fisher’s exact test) in canonical pathway analysis 
and calculated z-scores and P values in upstream regulator analysis.  The activation z-
score predicts the activation state of the upstream regulator, using the gene expression 
patterns of the genes downstream of that regulator. An upstream regulator is considered 
activated if the z-score is ⩾2 and inhibited if the z-score ⩽−2 with a P value <0.01 
considered significant. The Database for Annotation, Visualization and Integrated 
Discovery (DAVID) v6.7 was used for molecule classification within gene lists.  
Specifically, we identified secreted proteins and subsequently queried for G-protein 
binding or growth factor activity annotations. 
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5.3 Results 
5.3.1 Microarray analysis reveals exposure-specific gene profiles and 
injury severity gene profiles 
To identify differentially expressed genes in non-BO- and BO-inducing 
inhalation injury, mice were exposed to FA (filtered air), SO2 (500 ppm), low Cl2 (200 
ppm) or high Cl2 (350 ppm).  Tracheas were harvested for RNA extraction 5 days post 
exposure; this timepoint was chosen to reveal biological processes influencing the early 
stages of mesenchymal invasion into the airspace.  Agilent whole mouse genome 4×44K 
v2 arrays were used to analyze the expression profiles. Table 1 summarizes the number 
of gene targets found to be differentially expressed by ANOVA when compared across 
groups. The greatest number of gene targets resulted from comparisons of high Cl2 to 
either FA or low Cl2. To ascertain the global similarities among individual samples, we 
performed a principal component analysis (PCA) on unfiltered gene profiles (Figure 14). 
Within low Cl2 (yellow), high Cl2 (red), and FA (green) exposure groups, individual 
samples clearly cluster together, suggesting that they share similar expression profiles 
within groups. Additionally, the three exposure groups clearly separate from each other, 
suggesting there exists exposure-specific expression profiles.  
 However, individual samples from the SO2 (purple) exposure group did not 
cluster together.  Instead, two of the samples were similar to the FA group, while the 
other two samples were similar to low Cl2. The same trend is observed when we applied 
genome wide hierarchical clustering to the individual samples; FA, low Cl2 and high Cl2 
clustered separately but S02 was divided between FA and low Cl2 (Figure 15). We 
speculate that the division among the SO2 individuals was a result of inconsistent airway 
injury after exposure, in which two animals were injured and two were not injured. 
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According to previous studies, SO2 exposure results in airway epithelial injury similar to 
that of low Cl2 [105].  In our data, two of the SO2 exposed individuals clustered with the 
low Cl2. This suggested that gene expression profiles were indicative of gross airway 
injury. 
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Table 1: Total number of genes differentially expressed between groups. 
Using Partek analysis software, ANOVAs were preformed between all exposure groups. 
Analysis was restricted to genes with >3 or <-3 fold expression changes and a p<0.01. 
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Figure 14: Principle component analysis of global gene expression. 
In this analysis, the high-density gene expression data can be transformed into linearly 
uncorrelated variables called principle components. The samples are then graphed in 
three dimensions according to the 3 components with the greatest variance. The distance 
between individual samples correlates to expression profile similarity. PC #1 (x axis) 
accounted for 25.4%, PC #2 (y axis) 17.8%, and PC #3 (z axis) 11.1% of the observed 
variation for this data. Each point on the graph represents the expression profile of one 
sample. The colors for the exposure groups are as follows: low Cl2 (yellow), high Cl2 
(red), and FA (green). 
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Figure 15: Hierarchical and sample clustering. 
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Above is a heatmap of all genes with >3 or <-3 fold expression and p>0.05, generated by 
individual ANOVA comparisons of low Cl2, high Cl2, and SO2 exposure groups to 
filtered air. The samples were also clustered based on the similarity of their expression 
profiles.  
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5.3.2 Identification of enriched biological functions and canonical 
pathways in exposure-specific gene profiles 
Using Ingenuity Pathway Analysis (IPA), we evaluated the functional categories 
enriched within the transcription profiles induced by low and high Cl2. Table 2 lists 
significantly enriched functional annotations as compared to FA controls. Exposure to 
low Cl2 is primarily associated with cell cycle/proliferation functions (e.g. “refolding of 
protein”, “differentiation of cells”, “response of cyclic AMP”). The functions predicted 
by IPA were compatible with histologic features of the airway 5 days after low dose Cl2 
exposure. Specifically, the airway showed few inflammatory infiltrates and was covered 
with differentiating epithelium. Conversely, the analysis of high Cl2 revealed functions 
related to “inflammatory responses”, “activation of leukocytes”, and “cell movement”. 
These findings strongly corresponded to our histologic observations; 5 days after high 
dose Cl2 exposure, large areas of the trachea were denuded, and CD11b+ myeloid and 
collagen-producing cells were infiltrating the intraluminal compartment. The statistical 
significance of functions associated with high Cl2 are orders of magnitudes greater than 
low Cl2, and all high Cl2 annotations were strongly predicted to be activated (as 
indicated by the z-score). 
Next we used IPA to identify canonical pathways that were represented in our 
high vs. low Cl2 dataset.  IPA compares the input gene list to libraries of canonical 
pathway gene lists and then determines a p value that represents the probability that the 
overlap between the two lists was generated by chance. Table 3 summarizes the top ten 
canonical pathways that are enriched after high Cl2 compared to low Cl2 exposure. In 
agreement with the functional analysis, pathways reflecting immune cell migration and 
activation are upregulated. These include granulocyte and agranulocyte adhesion and 
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diapedesis, LPS/IL-1 mediated inhibition of RXR function, communication between 
innate and adaptive immune cells, and TREM-1 signaling.  Interestingly, two anti-
inflammatory pathways are predicted to be activated, inhibition of matrix 
metalloproteases and IL-10 signaling. This suggests that there may exist a natural 
process for dampening the inflammatory response. 
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Table 2: IPA generated function annotations. 
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Table 3: IPA generated canonical pathways. 
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5.3.3 Predicted activation of signaling molecules 
Pathway identification can be difficult because not all molecules in a biological 
pathway need be upregulated at the transcriptional level in order for the pathway to be 
biological significant.  To overcome this challenge, we used IPA’s upstream regulator 
tool to predict transcriptional regulators that most likely account for our observed gene 
expression profiles (Table 4).  IPA generated these predictions using extensive 
knowledge databases complied from publications on protein interactions, 
transcriptional factors and signaling networks. The algorithm assigns each factor a z-
score that is indicative of the factor’s activity.  A z-score > 2 or <-2 is considered to be 
significantly active or inactive, respectively. The most strongly predicted transcriptional 
regulators are NFκB, TBX2, SPI1, E2F1 and RELA.  Transcripts for SPI1 and E2F1 are 
elevated in our array dataset and regulate myeloid cell differentiation and cell cycle, 
respectively [106, 107]. RELA is one component of the NFκB complex, a major regulator 
of inflammatory genes [108]. TBX2 is a master regulator of organogenesis and has been 
implicated as an inducer of epithelial-mesenchymal transition [109].  
To broaden our list of potential therapeutic candidates we used IPA to explore 
predicted upstream signaling molecules other than transcription factors. Table 5 lists all 
predicted signaling kinases, growth factors, and transmembrane receptors with a z-score 
> 3. The fold increase of the molecule is indicated when applicable, but the majority of 
molecules were not elevated > 3 fold in our dataset (based on our ANOVA criteria). We 
will focus on some of these molecules in the discussion section.  
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Table 4: IPA predicted upstream transcription regulators. 
IPA analysis was based on the dataset generated by ANOVA comparison of high vs. low 
Cl2 exposure; the dataset was restricted to genes with >3 or <-3 fold expression changes 
and a p<0.01. 
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Table 5: IPA predicted upstream regulators. 
IPA analysis was based on the dataset generated by ANOVA comparison of high vs. low 
Cl2 exposure; the dataset was restricted to genes with >3 or <-3 fold expression changes 
and a p<0.01. 
 
 
 
 77 
 
5.3.4 Increased transcripts of soluble receptor-binding ligands 
We also evaluated our original dataset without the assistance of IPA. In table 7 
we simply listed all soluble proteins from our original dataset generated from the 
ANOVA comparison of high vs. low Cl2. Dynamic changes in ligand transcription could 
implicate ligand-associated signaling pathways as biologically significant in our injury 
model. We specifically identified guanosine nucleotide-binding protein (G-protein) 
ligands, because G-protein receptors make efficient therapeutic targets due to their 
signal amplification ability. Additionally, we identified ligands capable of inducing 
growth factor activity.  Some of these molecules have already been implicated in fibrotic 
processes but not necessarily in BO development. 
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Table 6: Upregulated soluble receptor-binding ligands.  
Using the Database for Annotation, Visualization and Integrated Discovery (DAVID), 
we identified receptor-binding ligands and divided them by their growth factor or G-
protein coupled receptor binding associations. Our input dataset was generated by 
ANOVA comparison of high vs. low Cl2 exposure; the dataset was restricted to genes 
with > 5 fold expression changes and a p<0.01. 
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5.3.5 Transcripts related to the angiogenic CXCR2 pathway are 
increased 
In chapter 2, we presented data suggesting that neovascualrization was VEGF-
independent in our BO model. In recent years, an alternative angiogenic pathway has 
emerged; several publications demonstrated CXCR2 mediates angiogenisis in multiple 
disease models, including a hetertrophic transplant BO model and tumor models [73, 
88]. To determine if our microarray data implicates either angiogenic pathway, we 
searched our dataset for upregulated surface receptors and ligands associated with 
VEGFR and CXCR2 pathways; we used the dataset generated from our ANOVA 
comparison of high vs. low Cl2. Table 8 lists our findings. For the CXCR2 pathway, the 
receptor itself was highly upregulated at the transcript level (77.7 fold change). 
Transcripts of the following CXCR2 ligands were upregulated; Cxcl7, 3, 2, 5, and 1 
(listed in order of decreasing fold expression). In stark contrast, our search for VEGF 
receptors and ligands generated no results. This strongly suggests that the CXCR2 
pathway is more active than the VEGFR pathway in our model. 
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Table 7: Upregulated transcripts associated with the CXCR2 or VEGFR pathways. 
Our input dataset was generated by ANOVA comparison of high vs. low Cl2 exposure; 
the dataset was restricted to genes with > 3 fold expression changes and a p<0.01. 
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5.4 Discussion 
The signaling pathways contributing to the pathogenesis of BO are unclear. To 
our knowledge, we are the first to use microarray technology to obtain a transcription 
profile of chemically induced BO. By comparing BO-inducing to non-BO-inducing 
injuries we reasoned that our datasets would reflect biological processes of BO 
exceeding normal airway repair. Our findings add support to suspected pathways in BO 
development and more importantly, suggest potential new pathways as mediators of 
BO. Future exploration of these pathways will require extensive validation and 
therapeutic evaluation in vivo. For now, we will discuss the merits of our findings in the 
context of histopathologic evidence and current literature on BO and other fibrotic 
diseases. We will divide our discussion into several parts, focusing on canonical 
pathways, upstream regulators and soluble ligands, CXCR2 angiogenesis, and final 
remarks.  
 5.4.1 Canonical Pathways 
The top 5 canonical pathways enriched in our analysis included three overt 
pathways and two less common pathways that have not yet been associated with BO 
development. The three overt pathways include 1) granulocyte and 2) agranulocyte 
adhesion and diapedesis, and 3) communication between innate and adaptive immune 
cells. By histological observation, it is obvious that tracheas of high Cl2-exposed mice 
have robust airway infiltration of granulocytes (neutrophils) and agranulocytes 
(monocytes, macrophages) into the airspace at day 5. This robust infiltration is not 
observed after low dose Cl2 exposure. Therefore, upregulation of migration and 
adhesion molecules is requisite for these cells to enter and remain in the airway. The 
canonical pathway “communication between innate and adaptive immune cells” is not 
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as overt because, as of yet, we have not extensively quantified immune cells traditionally 
associated with adaptive immunity (e.g. lymphocytes).  However, the canonical 
pathways are chosen based on the number of overlapping molecules in the canonical 
pathway and the dataset of interest. The majority of overlapping molecules represented 
more strongly innate cells and/or immature myeloid cells than adaptive cell types. In 
the next two sections we will discuss the less obvious canonical pathways and how they 
might contribute to BO pathology. 
5.4.1.1 IL-1β/LPS inhibition of retinoid x receptors 
IL-1β/LPS inhibition of retinoid x receptors (RXR) is the third canonical pathway 
predicted to be activated. RXRs are nuclear hormone receptors that function as ligand-
dependent transcription factors. The ligands for RXRs are retinoids, more commonly 
known as vitamin A and its derivates. RXRs are capable of forming homodimers and are 
common dimerization partners for other nuclear hormone receptors (e.g. retinoic acid 
receptors (RAR), peroxisome proliferator-assoicated receptor, liver X receptor) [110]. The 
distinct roles of RXR homo- and heterodimerization are not fully understood, but it is 
clear that responses are influenced by the nuclear receptor combination[110]. 
 The IL-1β/LPS inhibition of RXR pathway was initially described in the liver 
upon observation that LPS stimulation resulted in a rapid repression of hepatic genes; 
this response is known as the negative hepatic acute phase response [111]. Later, it was 
demonstrated in the liver that LPS or IL-1β caused rapid reductions in nuclear levels of 
RXR, the major regulator of the hepatic genes involved in the acute phase response [112, 
113].  It is unclear if a similar mechanism of RXR inhibition occurs in other tissues 
during infection or inflammation. 
To our knowledge the IL-1β/LPS inhibition of RXR pathway has not been 
identified in the development of BO. Out of the 241 genes that comprise this canonical 
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pathway, 48 genes overlap with our high vs. low Cl2 dataset. Transcripts of major 
upstream regulators of this pathway are increased, including IL-1β, TNFs, and TLRs (i.e. 
TLR1, 2, 6, 7, 8, and 13).  Many transcripts of genes regulated by RXR are downregulated 
(data not shown). But without additional interrogation of the pathway in our model 
there is no implicit data to support this finding. However, there are several lines of 
evidence demonstrating that therapeutic agonism of RXR or RXR/PPAR elicits anti-
inflammatory and anti-fibrotic responses; therefore such a therapy may be beneficial in 
our model. For example, in vitro retinoid treatment of activated macrophages resulted in 
decreased production of TNF-α, IL-12, and nitric oxide and increased production of the 
anti-inflammatory cytokine, IL-10 [114-116]. As shown in chapter 2, our BO model 
includes early invasion and accumulation of activated myeloid cells in the tracheal 
airspace. As a mechanism of action, we would predict that RXR angonism might 
suppress myeloid cell production of pro-inflammatory cytokines. Additionally, 
treatment of mice with RXR or RXR/RAR agonists resulted in the attenuation of liver 
fibrosis, kidney fibrosis, and radiation- and bleomycin-induced pulmonary fibrosis [117-
119].  Our array data has predicted that the RXR pathway is turned “off” during the 
progression of BO. Turning “on” the pathway merits therapeutic consideration based on 
its anti-inflammatory and anti-fibrotic effects. 
5.4.1.2 TREM-1 signaling 
Triggering receptor expressed on myeloid cells 1 (TREM-1) is a 30kDa 
glycoprotein receptor and a member of the Ig superfamily. Myeloid cells constitutively 
express TREM-1 and upregulate it further when activated. This receptor was initially 
thought to be myeloid cell specific but increasing reports of TREM-1 expression on 
human airway epithelium suggest a broader distribution [120]. Activation of TREM-1 
leads to the production of pro-inflammatory cytokines such as, TNFα, IL-1β, and IL-6.  
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Recently, platelets were confirmed as a ligand for TREM-1, but most likely there exist 
other unknown self and non-self ligands [121]. A soluble form of TREM-1 is generated 
by matrix metalloproteinase-mediated catalytic shedding; soluble TREM-1 is thought to 
compete for ligand as an inhibitory mechanism [122]. 
TREM-1 functions as an initiator and amplifier of inflammation in both infectious 
and non-infectious scenarios.  For example, in a murine sepsis model, inhibition of 
TREM-1 signaling using either the soluble form of TREM-1, a small peptide TREM-1 
antagonist, or siRNA techniques decreased inflammatory cytokines and improved 
survival [123-125]. The bulk of TREM-1 research has been investigated in the context of 
infections, but recently TREM-1 has gained recognition for its emerging role in the 
pathogenesis of non-infections diseases. Therapeutic targeting of TREM-1 has resulted in 
attenuation of collagen-induced arthritis, and mice deficient for Trem1 demonstrated 
attenuated hepatocellular carcinogenesis [126, 127]. TREM-1’s contribution to sterile 
inflammation requires further investigation. 
Due to its shot intracellular domain, TREM-1 must associate with DAP12, a 
transmembrane adaptor protein, for signal transmission. Upstream signaling molecules 
include, Src, Syk, and Btk [128, 129]. Engagement of TREM-1 with DAP12 results in Src-
mediated phosphorylation of DAP12, followed by phosphorylation of Syk and then Btk. 
Subsequent signaling molecules include, but are not restricted to, PI3K, PLCy, ERK 1/2 
and NTAL. Increasing evidence shows that TREM-1 is capable of synergistic crosstalk 
with pattern recognition receptors, namely TLRs and NLRs [128].   
TREM-1 signaling is the fifth canonical pathway predicted by IPA to be activated 
after exposure to high Cl2.  Out of the 71 genes that comprise TREM-1 signaling, 20 
genes overlap with our high vs. low Cl2 dataset. As of yet, TREM-1 signaling is not 
implicated in the pathogenesis of BO. However it is reasonable to predict activation of 
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TREM-1 in our BO model for the following reasons. 1) TREM-1 is primarily expressed 
on myeloid cells, and we histologically confirmed that activated myeloid cells infiltrate 
the airspace. 2) Transcripts of vital TREM-1 signaling components, DAP12, Syk and Btk 
are elevated in our dataset. 3) Transcripts of TREM-1 target genes are elevated (Il-1β, Il-
6, TNFα, CCL2, CD86). 4) The TREM-1 pathway can be activated by and synergize with 
TLR pathways. Our data indicated increases in several TLR transcripts.   
A proposed mechanism of action for TREM-1 in BO pathology is as follows: 
TREM-1 may initiate inflammation or enhance TLR-activated inflammatory processes of 
the myeloid cells infiltrating the airway. A persistent pro-inflammatory environment 
may sustain immune-mediated airway damage, resulting in delayed repair or, 
alternatively, it could perpetuate a program of inappropriate mesenchymal activation 
and chemoattraction into the airway. Due to the predicted activation of TREM-1 in our 
BO model and a successful history of TREM-1 therapeutic inhibition in other disease 
models, it will be interesting to evaluate the effects of TREM-1 inhibition in reducing 
inflammation and progression of BO in our model. 
5.4.2 Predicted upstream regulators and enriched soluble mediators. 
Kinases are attractive therapeutic targets; in the last decade small molecule 
inhibitors were developed that prevent kinase-specific signal transduction. For this 
reason we used IPA to query predicted upstream kinases. The top two candidates are a 
part of the inflammatory NFκB signaling pathway. This predicted activation is 
reasonable given the severe injury observed post Cl2 exposure. The ERK 1/2 pathway 
was also identified. Previous literature suggests a role for this pathway in BO 
pathogenesis. In a heterophic transplant model of BO, CCR1 and CCR5 antagonism 
resulted in an approximately 60% reduction of tracheal occlusion. The authors correlated 
this to reduced ERK inhibition[130].  In humans, prophylactic treatment of BO with 
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macrolides such as azithromycin reduced the incidence of BO two years post transplant 
[131]. The drug was reported to inhibit ERK 1/2 as well as NFκB signaling[132].  
However, it remains to be shown whether the drug’s mechanism of action is via the 
prevention of inflammation-induced epithelial damage or suppression of fibrotic 
processes or both. Our model would be ideal to test the role of ERK 1/2 in the fibrotic 
processes leading to BO.  
The top IPA predicted growth factors include epidermal growth factor (EGF) and 
hepatic growth factor (HGF). Dysregulation of EGF is associated with cancer and to a 
lesser extent with fibrosis. It has been reported to enhance mesenchymal survival and 
proliferation [133]. However, it is also important for epithelial cell survival and wound 
healing[133, 134]. The pleiotropic nature of the EGF pathway may preclude its use as a 
therapeutic. To our knowledge, EGF has not been associated with BO, and EGF was not 
identified as an upregulated transcript in our ANOVA analysis. In contrast, the other 
predicted growth factor, HGF, was upregulated 11-fold. Therapeutic administration of 
this ligand was demonstrated to reverse fibrosis in a bleomycin-induced murine model 
of pulmonary fibrosis. Evidence suggested that HGF induced myofibroblast apoptosis 
and extracellular matrix degradation [135, 136]. The role of HGF in BO is not known. We 
can speculate that our detected HGF upregulation indicates a natural anti-fibrotic 
response in the injured trachea. However, if there is a natural anti-fibrotic response, it is 
not strong enough to prevent fibrosis in our model. It would be interesting to test if 
augmenting natural HGF with recombinant HGF could attenuate fibrosis. 
Our query of upregulated soluble ligands resulted in the identification of pro-
inflammatory molecules including IL-6, IL-1β, IL-1α and TNFs. In particular, TNFs were 
enriched in our dataset suggesting that the TNF pathway is an important mediator of 
BO. Several lines of evidence in the literature support this idea. One particularly 
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informative study used a herterotopic transplant BO model to demonstrate that 
neutralization of TNF prevented transplant obstruction[137]. Neutralization of IL-1β was 
partially protective while neutralization of INF-γ or IL-6 was ineffective. In humans, 
elevated levels of TNF, IL-1β, TGFβ, and IL-8 have been reported in BALF from BO 
positive transplant patients[138-140]. However, these human clinical findings are highly 
variable. As mentioned above, azithromycin is a promising therapy for preventing BO; it 
is proposed to work via inhibition of the ERK and NFκB signaling pathways[141, 142]. 
Inhibition of these pathways it is thought to reduce pro-inflammatory cytokines, TNFα 
in particular. Whether the benefits in the above studies are a result of reduced tissue 
damage or suppression of fibrotic processes or both is unclear. Our data suggests that 
the TNF pathway may be an important regulator or initiator of fibrosis since our gene 
expressions were measured during early fibrotic changes in our model. It will be highly 
interesting to assess the affect of TNF neutralization or azithromycin on BO 
development after Cl2 exposure.  
5.4.3 CXCR2 
One particularly interesting finding is that CXCR2 and its ligands are enriched in 
our microarray analysis. In chapter 3, we demonstrated that VEGFR-2 inhibition was 
insufficient to prevent BO after Cl2-injury. In the discussion that followed, we proposed 
that an alternative CXCR2 pathway might mediate angiogenesis in our model. This 
hypothesis was additionally supported by a previous publication demonstrating that 
CXCR2 mediates angiogenesis in a heterotrophic transplant model of BO.  However we 
did not have any experimental data to support this claim. Our microarray analysis 
allowed us to unbiasedly evaluate the enrichment of both VEGFR and CXCR2 pathways 
via upregulation of their respective receptors and ligands. Strikingly, no upregulated 
genes were detected in association with VEGFR. In contrast, CXCR2 and five of its 
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ligands were increased. These findings strongly suggest that the mechanism of 
neovascularization observed in the transplant model of BO is similarly active in our 
model. The same transplant publication reported that mRNA expression and protein 
levels of CXCL2 and 3 increased over the course of BO development, with maximum 
expression coinciding with fibroproliferation. Similarly, we detected elevated CXCL2 
and 3 transcripts.  
Our microarray analysis was able to identify an angiogenic pathway already 
implicated in the pathogenesis of BO. Validation of this pathway in our model could 
lead to exciting new insights into the pathogenesis of BO. For instance, there are 
significant differences between a transplant and chemical-induced BO model; including 
rejection-dependency and airway vs. subcutaneous location of the trachea. Validation of 
CXCR2-mediated angiogenesis in our model would suggest that it is a universal 
mechanism of BO shared by all inciting events. However, further experimentation is 
required before we can make such claims. 
5.4.4 Concluding remarks and future directions 
To our knowledge, only one study has published microarray-based gene 
expression analysis for a murine model of BO.  Lande et al. conducted microarray 
anaylsis of isografts and allografts in a murine heterotophic tracheal transplant model of 
BO [143].  The majority of elevated transcripts were associated with T cell activation and 
humoral immunity, which limited their ability to identify genes associated with fibrosis 
and fibroproliferation. Our present analysis offers several advantages over this previous 
study. 1) Our chemical-induced BO model is not allorejection dependent and 2) avoids 
possible off-target findings that could arise from surgical tissue damage or 3) arise from 
exposure to extrapulmonary environments (subcutaneous relocation). 4) The BO 
developmental timeline is more synchronized in our model since mature epithelial 
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damage is immediate upon chemical inhalation and occlusive fibrosis occurs 
approximately 9 days post injury. Conversely, transplant BO models have longer 
timelines since immune-mediated epithelial damage occurs approximately 7 days post 
transplant, followed by fibrosis approximately 20 days post transplant. A more 
synchronized pathogenesis may lead to less variation in gene expression among 
individuals. Taken together, we argue that our gene expression increases are less likely 
to be dominated by alloimmune responses, allowing for greater sensitivity in the 
identification of underlying disease mechanisms. And finally, 5) the previous paper was 
published in 2005. Over the last eight years, analysis software, like IPA, has greatly 
improved and provides keen insight into the pathways represented in transcriptional 
profiles. 
Studies in humans have attempted to link genetic polymorphisms to the 
occurrence of BO after lung transplantation. The most prominent findings are IFNG, 
TGFB1, and IL6 functional polymorphisms that generally exacerbate inflammation and 
fibrosis[144].  However the sample sizes for many of these studies are small and findings 
between studies have been inconsistent.  It is unclear which pathogenic events these 
genetic variations most greatly influence or if they are applicable to non-transplant BO. 
In our analysis, only IL-6 is upregulated. But as mentioned previously neutralization of 
INF-γ or IL-6 was ineffective at preventing airway obliteration in a herterotopic 
transplant BO model[137]. In sum, we do not consider INF-γ, TGF- β or IL-6 primary 
candidates for mediators of BO in our model. 
We must concede that microarray analysis and subsequent pathway analysis is 
not without its limitations. It is important to note that a normal trachea is very different 
after injury, in terms of activation and cellular content. Due to such dramatic changes in 
cellular composition, it can be difficult to determine if an enriched pathway is 
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biologically significant in the pathogenesis of BO or whether the pathway is enriched 
because it is a bystander pathway in a newly recruited cell type. Additionally, when 
trying to analyze complex biological processes from a whole genome screen, we assume 
that some of the analysis will garner false positives or overlook potential pathways 
entirely. As was the case when we independently queried our dataset and identified 
CXCR2 as a potential regulator of angiogenesis, a pathway not identified by IPA. 
However, we were able to confirm the general accuracy of IPA’s functional analysis by 
comparing it with our extensive knowledge of the histopathologic progression of Cl2-
induced BO. But the real power of gene expression analysis is not confirming what is 
known, but suggesting what is unknown. 
Our analysis has narrowed our focus to a few choice pathways for future 
investigation. To our knowledge, the two canonical pathways, TREM-1 signaling and 
RXR, have never before been associated with BO. Due to their associations with 
inflammation and/or fibrosis, both pathways merit future interrogation for their role in 
BO pathogenesis. These pathways can be targeted using TREM-1 neutralizing antibodies 
and RXR agonists, respectively. Additionally, we will investigate the role of ERK, NFκB, 
and TNF signaling pathways. These pathways are already associated with BO although 
their mechanisms of action are unclear.  Using our model, we will be able to assess their 
pathological contributions to BO, particularly their contributions to fibrotic processes 
after significant inciting epithelial cell damage. Modulation of these pathways can be 
achieved using small molecule inhibitors or, in the case of TNF, neutralizing antibodies. 
We also plan to revisit neovascularization in our model now that our data suggests the 
process is mediated by CXCR2. CXCR2 has multiple ligands, but by using a CXCR2 
antibody antagonist we should be able to prevent CXCR2 signaling and determine its 
effect on neovascularization of BO lesions post Cl2 injury. Our findings are only the start 
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for dissecting apart the complex processes that fuel BO. We will move forward with 
validating the activation of our chosen targets and evaluating their contribution to BO 
pathogenesis in vivo.    
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6. Cellular recruitment and accumulation in the lung after 
exposure to moderate Cl2 concentrations  
6.1 Introduction 
Whereas in earlier chapters we focused on fibrotic consequences following high 
concentrations of Cl2, in this chapter we will focus on inflammation in the lower airways 
and lungs following exposure to moderate concentrations of Cl2. Acute inhalation of 
toxic chemicals such as Cl2 causes a spectrum of clinical syndromes in humans.  Direct 
mechanisms of Cl2 primarily involve oxidative damage to the airway and were 
discussed in the introduction. Indirect mechanisms are not clearly understood. In 
chapter 5, we concluded that NOS2 did not contribute to the fibrotic pathology observed 
in our Cl2-induced BO model; however, previous studies have highlighted the 
importance of NOS2 in other Cl2-induced syndromes by demonstrating that 
prophylactic pharmacological inhibition of NOS2 mitigated AHR after Cl2 injury [99]. 
However, after Cl2 exposure, the pathology-driving source of NOS2 has not been 
indentified.  
Previously our lab demonstrated that CCR2+ inflammatory monocytes mediated 
immune pathology in a model of influenza infection and that pharmacologically 
inhibiting recruitment of these cells to the site of injury mitigated disease severity [92]. 
Once recruited to the lung, inflammatory monocytes differentiated into inflammatory 
dendritic cells and exudate macrophages that produced tissue-damaging levels of TNFα 
and NOS2. Since trafficking of inflammatory monocytes into inflamed tissue is CCR2-
dependent, Ccr2-deficient mice have impaired recruitment of these cells into the lung 
after injury [92, 145-147]. We reported that influenza-induced morbidity and mortality 
were reduced in Ccr2-deficient mice and in wild-type mice when treated with a CCR2 
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antagonist[148]. Correlating with fewer inflammatory monocytes, NOS2 expression was 
also significantly reduced[92].  
Here, we propose that CCR2+ inflammatory monocytes and their derivates, 
exudate macrophages, are a pathologic source of NOS2 after Cl2 injury. In this chapter, 
we evaluated inflammatory monocyte and exudative macrophage accumulation in Cl2-
exposed lungs and determined the effects of CCR2 deficiency and NOS2 deficiency on 
the accumulation of inflammatory cells in the lungs of Cl2-exposed mice. 
6.2 Materials and methods 
Mice. C57BL/6 and Ccr2-deficient were purchased from Charles River 
Laboratories (Wilmington, MA) and Nos2-deficient mice (stock # 002596) were 
purchased from Jackson Laboratory (Bar Harbor, ME). All animal experiments were 
conducted in accordance with National Institutes of Health guidelines and protocols 
approved by the Animal Care and Use Committee at Duke University. 
Chlorine exposure. Mice were exposed as described in chapter 2 with the 
exception that all Cl2 concentrations were 190ppm.  
Lung cell isolation and flow-cytometric analysis. Lungs were slowly perfused 
with 3-5 ml of cold PBS and then maximally inflated with digestion media: 1.5 mg/ml 
collagenase, 0.4 mg/ml DNase I, 5% FBS and 10mM HEPES in HBSS. The lung lobes 
were dissected from the rest of the airway and digested in 5 mls of digestion media at 37 
degrees C for 30 minutes. Tissues were gently vortexed every 10 minutes during 
incubation. 25 mls of PBS were added and the tissues were vigorously vortexed for 30 
seconds. The disassociated tissue was strained through a 70µm cell strainer. Cells were 
washed and red blood cells lysed. Cells were resuspended in 5 mls of PBS.  5x106 cells 
were stained in PBS with Live/Dead Aqua (Molecular Probes, Grand Island, NY). Cells 
were washed then blocked for 10 minutes at 4 degrees C in a blocking buffer: 10 mM 
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EDTA, 1% BSA, 5% normal mouse serum, 5% normal rat serum, and 1% Fc block 
(eBioscience, San Diego, CA) in PBS. Cells were stained with antibodies for 30 min, total 
volume 100ul, then washed three times and analyzed using a BD LSRII flow cytometer. 
Antibodies used included: CD49b-PE, CD11c-PerCP-Cy5.5, CD45-Qdot605, IA/IE-
Qdot655 from eBioscience and CD11b-PE-Cy7, Gr-1-APC-Cy7, Ly6G-V450 from BD 
Pharmingen (San Jose, CA). 
Statistics. All numerical data are presented as mean ± SD. All data are analyzed 
by Student’s t tests using Prism software (GraphPad, San Diego, CA) as indicated in the 
figure legends. 
6.3 Results 
6.3.1 Monocyte-derived macrophages and dendritic cells do not 
accumulate in the lungs after moderate Cl2 inhalation 
Previous histopathologic and bronchoalveolar lavage data have shown an 
accumulation of inflammatory cells, such as neutrophils and macrophages, in the 
airways after Cl2 exposure [56, 99, 149, 150], but no one has specifically shown 
inflammatory monocyte and exudate macrophage accumulation in the lung. Monocyte 
and macrophage subsets have similar morphologies and can only be differentiated using 
a combination of surface markers that are specific to each subset [151]. Our lab 
developed a flow cytometry protocol consisting of 10 surface antigens that allowed us to 
label and quantify the majority of myeloid cell subsets in homogenized lung tissue. 
Using this protocol we expanded upon previous morphology-based myeloid cell 
enumerations and quantified phenotypically different myeloid subsets within lung 
tissue after Cl2. Our gating strategy for quantifying cell populations is outlined in Figure 
16A.  We began our investigation by analyzing inflammatory cell recruitment into the 
lungs 3 and 8 days post exposure to 190ppm of Cl2. Specifically, we investigated exudate 
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macrophage accumulation. Lin et al. identified exudate macrophages as CD11b+, 
CD11c+, MHCIIhigh, and Gr-1high upon recent recruitment into the lung [92]. In agreement 
with previous literature, we found that exudate macrophages are not present at baseline 
(Figure 16B). However, our results also showed that exudate macrophages do not 
accumulate in the lungs on day 3 (Figure 16B) or day 8 (data not shown) post Cl2 
exposure. Additionally, we did not observe the accumulation of any new populations 
exceeding baseline populations (data not shown).  
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Figure 16: Representative gating strategy for quantification of myeloid subsets.  
A) Gating strategy in a FA-exposed mouse. Surface marker expression of myeloid 
subsets are as follows: neutrophils (CD45+, Ly6Ghigh); alveolar macrophages (CD45+, 
CD11chigh, IA/IEint, Autofluorescent+, CD11b-); dendritic cells (CD45+, CD11cint/hi, 
IA/IEhigh, Autofluorescent-, CD11b+/-); inflammatory monocytes (CD45+, CD11c-, IA/IE-, 
CD11b+, Gr-1+); constitutive monocyte (CD45+, CD11cint, IA/IE-, CD11b+, Gr-1-). B) 
Historically, exudate macrophages are present in the IA/IE+, CD11c+ gate and are Gr-1 
hi. 3 days post Cl2 exposure, no exudate macrophages are detected. 
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6.3.2 Effect of CCR2 deficiency on inflammatory cell infiltration and 
accumulation in the lung 
CCR2 and its ligand MCP-1 comprise a major axis of chemoattraction mediating 
inflammatory monocyte recruitment into inflamed tissue. Ccr2-deficient mice have 
impaired recruitment of these cells into inflamed tissue. We investigated whether CCR2 
deficiency affects the accumulation of myeloid cell populations after Cl2 injury.  
In wild-type mice, there was no significant change in myeloid cell populations 
after Cl2 inhalation; these include alveolar macrophages, dendritic cells, neutrophils, 
inflammatory monocytes and constitutive monocytes (Figure 17, white bars). In 
agreement with previous studies, Ccr2-deficient mice have significantly fewer 
inflammatory monocytes at baseline, approximately 4-fold reduction [92, 152](Figure 17, 
black lines). This trend was significant and persisted at all timepoints. Additionally, 
alveolar macrophages and dendritic cell numbers were significantly reduced at baseline 
compared to wild-type. These reductions have not been previously reported and may be 
an incidental finding. We found no other differences between wild-type and Ccr2-
deficient mice that we deemed potentially biologically significant. 
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Figure 17: Quantification of lung myeloid cell populations in Ccr2-deficient mice. 
Mice were exposed to 190 ppm Cl2. On days 3 and 8 post exposure, lung homogenates 
were stained for flow cytometric analysis. Using the gating strategy from Figure 16, 
myeloid cell populations were quantified for wild-type (B6; n=9-10 mice per timepoint) 
and Ccr2-deficient (CCR2; n=8-10 mice per timepoint). *, p<0.05 by student’s t test, data 
are presented as mean ± SEM. 
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6.3.3 Effect of NOS2 deficiency on inflammatory cell infiltration and 
accumulation in the lung. 
Since a previous paper demonstrated that elevated AHR after Cl2 inhalation was 
NOS2-dependent, we investigated whether Nos2-deficient mice had different 
inflammatory cell accumulation after injury. Our results showed baseline differences 
between wild-type and Nos2-deficient mice, specifically, a 3-fold increase in 
inflammatory monocytes and a 2-fold decrease in dendritic cells (Figure 18). There was a 
trend toward fewer constitutive monocytes; this trend persists across all timepoints. To 
our knowledge these differences have not been previously reported and may be an 
incidental finding. Another possible explanation is that the Nos2-deficient mice are on a 
129 genetic background and the control is a wild-type C57Bl/6. It is known that tissue 
resident cell numbers can differ according to genetic background. After Cl2 injury, cell 
populations in Nos2-deficient mice did not significantly change from baseline 
measurements. We found no accumulation of exudate macrophages in Nos2-deficient 
mice (data not shown) and no other cellular differences that we deemed potentially 
biologically significant. 
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Figure 18: Quantification of lung myeloid cell populations in Nos2-deficient mice. 
Mice were exposed to 190 ppm Cl2. On days 3 and 8 post exposure, lung homogenates 
were stained for flow cytometric analysis. Using the gating strategy from Figure 16, 
myeloid cell populations were quantified for wild-type (B6; n=4-5 mice per timepoint) 
and Nos2-deficient (iNOS; n=4 mice per timepoint). *, p<0.05 by student’s t test, data are 
presented as mean ± SEM. 
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6.4 Discussion 
Cl2 inhalation results in airway abnormalities that are in part mediated by 
inflammation[99]. In this chapter, we demonstrated that CCR2+ monocyte-derived cells 
are not major contributors to inflammation after Cl2 injury. We based this conclusion on 
our findings that CCR2+ inflammatory monocytes did not significantly accumulate in 
the lung and, accordingly, CCR2+ monocyte-derived cells were not detected after injury. 
Multiple factors could contribute to our observed lack of recruitment into lung tissue. 
Firstly, moderate Cl2 exposure primarily damages the airway [149, 153, 154]. We take 
into consideration that our whole lung analysis may not be sensitive enough to reflect 
leukocyte infiltration and accumulation specific to the airway. Previous reports in Cl2-
injury models quantified cells from BALF[99, 149, 153]. This technique results in direct 
leukocyte sampling along the route of injury and not in the lung parenchyma. In 
addition, Cl2 injury is a sterile form of inflammation with no foreign immunogen to 
activate time-honed pathogen-associated molecular patterns (PAMPs). Significant 
recruitment and accumulation of myeloid cells in the lung is observed during PAMP-
activating viral [92, 97] or bacterial lung infection [155] suggesting that different 
inflammatory stimuli are more effective at recruiting inflammatory monocytes than 
others. 
We also observed that inflammatory cell populations in Nos2-deficient mice did 
not fluctuate from the Nos2-deficient baseline.  Our findings share the limitations 
mentioned above. Additionally, Nos2-deficiency most likely affects immune cell 
activation and effector functions instead of directly affecting immune cell trafficking. 
However, it is impossible to make conclusions about the effects of cellular 
accumulation or activation on the pathogenesis of Cl2-induced acute lung injury or 
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RADS without data linking observed changes to physiologic outcomes. The above 
studies were preliminary experiments to confirm the presence of exudate macrophages, 
a potential cellular source of NOS2. In this goal, we successfully confirmed that there 
was no accumulation of exudate macrophages in the lungs of Cl2 exposed mice. 
Therefore, exudate macrophages are not a pathogenic source of NOS2 in our model. Due 
to the meager recruitment of inflammatory cells into the lung, we suggest that future 
research should focus on resident immune cells, including alveolar macrophages, and 
non-immune cells, including the epithelial cells, as pathogenic sources of NOS2 in Cl2 
injury. 
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7. Final remarks  
This dissertation advances the field of BO research in several ways. First, we 
characterized a novel murine model of Cl2-induced BO. It is our hope that this model 
becomes a staple in BO research as it offers several distinct advantages over traditional 
transplant BO models, including allorejection independence and greater feasibility in 
terms of technique and throughput. Additionally, the well-demarcated series of 
pathological changes in our model will allow a more detailed analysis of the individual 
cellular and molecular events that lead from basal cell loss to airway occlusion. 
Secondly, by using this model we demonstrated that in the absence of basal cells, 
epithelial regeneration does not occur and regions of epithelial denudation persist from 
which an aberrant repair process is initiated, leading to obliterative airway lesions. Our 
findings suggest that, irrespective of the cause, loss of epithelial progenitor cells may be 
a critical factor leading to the development of BO.  We encourage further analysis of 
epithelial progenitor populations in other models of BO to fully ascertain the 
commonality of this inciting event.  Epithelial progenitor cells may become a novel 
therapeutic target for which therapies protect and sustain critical progenitor cells in the 
face of injury. And finally, to our knowledge, we are the first to use microarray 
technology to analyze gene expression profiles in a chemical-induced BO model. Our 
data identified molecular mediators already associated with BO pathogenesis, including 
CXCR2, TNFs, ERK, and NFkB.  But more importantly, it identified novel molecular 
mediators, including TREM-1, RXRs and HGF. However, these therapeutic targets 
require further validation. Our findings are only the start for dissecting the complex 
processes that drive BO pathogenesis. We fully expect that our Cl2-induced BO model 
will be an invaluable resource to systematically test our therapeutic targets for the 
prevention of BO.  
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